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Introduction: Mental illness is the leading contributor to disability, globally. The economic, 
social and individual cost of mental illness is high, being an indiscriminate health condition 
affecting all walks of life, gender, race and age. People with mild to moderate mental health 
conditions are generally cared for in primary health care with their drug treatment available 
from the community pharmacy. This gives the community pharmacist the ideal opportunity 
to interact with people with mild to moderate mental health conditions and play an 
important role in their care. To date, community pharmacists’ views on their roles and 
contribution to primary mental health care in New Zealand have not been investigated. 
Aim: To explore community pharmacists’ perceptions of their role in primary mental health 
care. 
Methodology: A qualitative study was undertaken. Fifteen face-to-face semi-structured 
interviews took place with registered community pharmacists from across New Zealand. 
Participants discussed current primary mental health services delivered by community 
pharmacists as well as facilitators and barriers to service provision. Interviews were audio-
taped and transcribed verbatim. Data obtained were then coded and common themes were 
identified using a thematic analysis approach. 
Results: Four main themes were identified. These themes showed that participants all 
believed they had an important role to play in primary mental health care. The level of 
interaction varied from the basic dispensing role, to dispensing plus patient counselling with 
provision of education and advice, through to broader patient centred primary mental 
health care. Community pharmacists could provide a continuum of primary mental health 
services which included multidisciplinary team care, patient support and patient advocacy. 
Factors identified that impacted on the ability to provide primary mental health care 
services included stigma, privacy and confidentiality issues, staffing levels, availability of 
time and funding, community pharmacists’ education and their perceptions of patient’s 
needs. 
Conclusion: As part of the primary health care team, community pharmacists are increasing 
their contribution to the provision of primary mental health care. This coincides with an 
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increased emphasis within policy and practice by government and pharmacy and medicine 
stakeholder organisations to support pharmacists to increase their face-to-face work in 
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Mental illness, an important public health concern, is indiscriminate in nature and found 
worldwide, across continents and cultures, affecting all ages and genders.1,2,3  Depression in 
particular, has been cited by the World Health Organization (WHO) as ‘the single largest 
contributor to global disability’, with 322 million people estimated to be affected, equivalent 
to 4.4 percent of the world’s total population.4 p5 Depression is not only linked with high 
disease burden and social disability, 5 but there is a significant associated economic cost 
with considerable loss of earnings and productivity.6 Mental illness can have an enormous 
impact, not only on the life of individuals, both physically and emotionally, but also their 
families, friends and carers and on society as a whole. It is also commonly known for people 
to be diagnosed with concurrent physical health and mental health conditions. The 
literature shows that there is often poorer physical health care and higher mortality 
associated with mental illness.7 Many health care professionals in primary health care are 
typically involved in the care of those with mental illness, usually the doctor or general 
practitioner (GP) in a community-based health service, who diagnoses and treats the 
condition, counsellors and therapists who can be involved in the treatment process, and the 
community pharmacist (CP) who dispenses the prescribed medication for treatment and can 
undertake additional roles for people in their care.  
1.2 Mental Health Burden in New Zealand 
In the He Ara Oranga: Report of the Government Inquiry into Mental Health and Addiction8  
published in 2018, it was stated that one in five New Zealand adults experience mental 
illness or significant mental distress at some time in their lives. Any person can be affected, 
and over 50-80 percent of New Zealanders will experience mental distress and or addiction 
challenges in their lifetime.8 People that experience psychological distress are highly likely to 
have an associated anxiety or depressive disorder. The 2012/13 New Zealand Health Survey9 
found that rates of psychological distress were significantly higher in Māori adults (10 
percent) and Pacifica adults (9 percent), compared with the general adult population (6 
percent).9 It was also stated in these statistics that New Zealand men are less likely to 
experience psychological distress (5 percent) compared with New Zealand women (7 
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percent). Depression and anxiety are thus conditions that are commonly seen in primary 
mental health care, and are described as mild to moderate mental illness. 
1.3 Treatment of Mild to Moderate Mental Illness in Primary Health Care Settings 
The widespread nature of mild to moderate mental illness and the large numbers affected 
resulted in the development of primary care treatment recommendations from the WHO. 
These included medicines and talking therapy and the recommendation that the 
medications to treat these conditions be available for all those in need.10 The drug 
treatment in mental illness has expanded greatly from the armoury of tricyclic 
antidepressants (TCAs) used in the 1960s to include a range of Selective Serotonin Re-
Uptake Inhibitors (SSRIs) and Serotonin and Noradrenaline Re-uptake Inhibitors (SNRIs), in 
common usage since the mid-1990s. With the medication for the treatment of depression 
and anxiety being dispensed on a regular basis from community pharmacies in New Zealand, 
CPs have the opportunity to interact with these patients on a regular basis. 
1.4 The Community Pharmacists’ Role and Health Policy Perspectives 
1.4.1 Key policies: expanding roles in primary health care 
The ‘The New Zealand Health Strategy’ (2000) and ‘The New Zealand Primary Health Care 
Strategy’ (2001), signalled the Ministry of Health’s vision for an increased role by primary 
health care professionals in New Zealand.11,12 These key policies emphasised accessibility 
and comprehensiveness of health care and collaboration in primary health care services and 
aimed to identify and remove health inequities in New Zealand. In 2005, the Ministry of 
Health (MOH) signalled a focus on the care of those with mild to moderate mental health 
conditions when they released funding to trial various primary mental health initiatives 
(PMHI). This funding was the first central funding by the MOH to directly and specifically 
support primary mental health care. These initiatives involved work within a small number 
of Primary Health Organisations (PHOs) with multidisciplinary primary health care 
professionals. The PMHI delivered a range of mental health services over a two-year period 
responding to patient need, and these were independently evaluated. The results showed 
that the mental health needs of mild to moderate mental illness could be successfully 




‘The New Zealand Health Strategy Future Direction’ (or refreshed New Zealand Health 
Strategy)14  released in April 2016 and ‘The Mental Health and Addiction Workforce Action 
Plan 2017-202115 continued to contribute to achieving the New Zealand Health Strategy 
vision from the year 2000. This vision focused on people thriving and experiencing well-
being, wherever they lived in New Zealand and whatever their circumstances. There was 
also a focus on building a multidisciplinary workforce to work as one team, integrating 
services across the health sector and increasing access to technology so that primary health 
care professions could work together to their full potential, providing health services to 
their communities.  
The role of CPs and their involvement in primary health care has not been specifically 
mentioned in any of these key policy documents to date. However, there has been 
documentation of CPs in the Pharmacy Action Plan 2016 to 202016 published in 2016 by the 
Ministry of Health. This plan proposed integration of CPs into the primary health care teams 
throughout New Zealand and the use of technology to share information and increase 
communication, thus enhancing the provision of pharmacy services for both primary and 
secondary health care members. This was put in place to help provide services to all New 
Zealanders, but specially to help those underserved minorities. These underserved 
minorities were defined as Māori, Pacific peoples, those with disabilities and those with 
mental health concerns.  
More recently, the New Zealand Health and Disability System Review was released in June 
2020. The review was chaired by Heather Simpson and had a series of recommendations to 
ensure the health and disability system is better balanced toward wellness, access, equity 
and sustainability.17 Since the publication of the review, the Pharmaceutical Society of New 
Zealand (PSNZ)18 has had a new value proposition of the pharmacy profession posted on its 
website. PSNZ states that New Zealand pharmacists are able to address access and equity 
challenges and are well prepared and able to deliver what is required, from the Health and 
Disability System Review. PSNZ states that pharmacists have the required training, the 
competence, the capability and capacity to address these challenges in the health care of 
New Zealanders. This includes pharmacists from multiple backgrounds encompassing both 
community and hospital pharmacists. PSNZ believes that pharmacists are not currently 
being used to their maximum potential to provide better primary health care and primary 
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mental health care. PSNZ claims it needs support from the government to provide the 
primary health care and primary mental health care as posited in the Health and Disability 
System Review. 
1.4.2 The community pharmacists’ role 
While New Zealand and offshore research have demonstrated the significant contribution 
CPs make in physical health conditions such as diabetes,19 cardiovascular disease20 and 
respiratory conditions,21 a great deal less research has been carried out and is known about 
New Zealand CPs’ roles in supporting those with primary mental health conditions. This is 
the focus of this research. 
1.5 Thesis Terminology 
For clarity, the definitions of the following terms used in this thesis are given below: 
Mild to moderate mental Illness: this study focuses on the role of the CP in relation to mild 
to moderate mental illness, which includes both the conditions depression and anxiety. This 
term is also sometimes known as common mental illnesses, or common primary mental 
health conditions. These are common conditions that are frequently seen by CPs in 
community pharmacies on a regular basis, often daily. People with these illnesses are 
usually cared for in the community, not under specialist mental health services or in the 
hospital, i.e. secondary health care. With support from their family or carers they are able to 
continue to live in their own home and undertake work responsibilities. This research does 
not extend to severe and persistent mental illness, and therefore excludes conditions such 
as major depression, schizophrenia, bipolar disorder or other psychotic disorders. 
Community pharmacist (CP): a qualified and registered health practitioner trained in the 
field of pharmacy, based in a retail pharmacy in a community setting. Typically, a CP 
prepares and dispenses medication for patients, alongside providing a number of services 
and activities, as shown in Appendix A. In New Zealand, the CPs’ role in primary mental 
health care includes dispensing medication used in the treatment of mental illness and 
giving advice and support for this treatment. One particular drug, Clozapine, that CPs are 
trained to dispense,22  is the drug of choice for more severe mental health conditions, not 
being indicated for mild to moderate mental illness, and therefore is not discussed here.  
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Patient: the terms patient, client, consumer, or service user are commonly used in studies 
and other research carried out in this area. In this study, people who have mild to moderate 
mental illness and use the services offered by CPs will be referred to as the ‘patient’. 
Patient counselling: commonly used by both community and hospital pharmacists in their 
routine communication with their patients. Patient counselling used in this context is 
different to patient counselling in areas specific to psychologists, counsellors or therapists. 
In pharmacy, the term is used when educating and giving information regarding drugs and 
their usage. Patient counselling covers topics such as the dosage of the drug, adverse 
effects, medication adherence, expected results or outcomes and additional underlying 
issues. It also includes general information regarding health services and lifestyle 
strategies.23,24 
1.6 Thesis Structure  
Chapter 2 provides a review of existing literature related to CPs and their role in primary 
mental health care. Chapter 3 presents the aims and objectives of this research, while 
Chapter 4 describes the methodological approach that was undertaken and explains the 
rationale for this research. Chapter 5 presents the results and Chapter 6 discusses these 
findings in light of the existing literature and describes the strengths and limitations of this 
research. Chapter 7 presents the conclusion and Chapter 8 describes the recommendations 
from this research. 
1.7 Researcher’s Background 
I have been involved in pharmacy in New Zealand for over thirty years, with an equal 
number of years of experience in both community and hospital pharmacy. I have also spent 
several years in the pharmacy education and learning sector. All of my pharmacy training 
has been in New Zealand and I am a New Zealand registered pharmacist. My community 
pharmacy experience has been in busy suburban dispensaries, working alongside many 
other CPs, dispensing large volumes of prescriptions daily, as well as working in small rural 
and central city pharmacies. All of these pharmacies have had close association with other 
primary health care providers in the area. My time spent in hospital pharmacy has been in a 
private hospital situation which specialised in elective surgery in multiple disciplines. My 
latest community pharmacy experience has been dealing with the Covid-19 pandemic 
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situation in New Zealand as the country went into lockdown and CPs were among the 
essential workers that continued working. This has demonstrated the important work of CPs 
in unprecedented and difficult times, dealing with all patients in times of stress and need.  
Continuing education of both pharmacy and nursing staff has been among my many 
interests spanning my pharmacy career. I have a special interest in the health quality and 




2. LITERATURE REVIEW 
 
This chapter contains the review of the literature relating to community pharmacists (CPs) 
and their role in primary mental health care. First there is a discussion on the connection of 
community pharmacy with general health care and why community pharmacy is well placed 
to provide support in health care. The role of the CP in relation to primary mental health 
follows by looking at services provided, first internationally then nationally. A review of 
factors that affect the provision of services concludes the chapter. 
2.1 Literature Review Methodology 
The literature search was initiated to look at CPs and their involvement in primary mental 
health care, which includes the CPs’ role and the pharmacy services they provide in this 
area. The search was limited to mild to moderate mental health conditions which included 
mild to moderate depression and anxiety, and excluded more severe mental illnesses such 
as severe and persistent depression, schizophrenia, bipolar or any other psychiatric 
disorders. However, in some cases the literature included reference to mental health care as 
a whole. With assistance from a specialist reference librarian, a search strategy was 
developed with alerts to identify new literature as it was published. Publications were 
searched in English, beginning from 1 January 2000 until 31 July 2019. Any additional 
literature that was subsequently found and thought to be relevant to this research has been 
added. The databases used in this search were EMBASE, Medline, Scopus, ProQuest, Science 
Direct, EBSCOhost and PsycINFO. The search terms used included the following: community 
pharmacist, role, mental health, pharmacy services, perceptions. These can be seen in 
Appendix B. The Boolean operators ‘AND’ and ‘OR’ were used to broaden or narrow the 
search, as necessary. When appropriate titles were found, the abstracts were scanned and if 
the paper was applicable the full texts were reviewed. Associated reference lists were a 
source for further information. Google Scholar was searched separately for appropriate 
information and a search of grey literature focused on publications from the Ministry of 





2.2 Mental Health Care and Community Pharmacy 
Evidence based practice for guidance in primary mental health conditions include several 
options which can be grouped into three main areas. First, exercise and self-management; 
second psychological interventions such as cognitive behavioural therapy, interpersonal 
therapy and problem-solving therapy; and third prescribed drug treatment.25,26 The 
provision of prescribed medication for primary mental health care from community 
pharmacy gives CPs the opportunity to interact with people with mental health issues and 
this is reinforced by treatment courses often being prescribed for considerable lengths of 
time. This allows for extended regular contact between the CP and the patient, resulting in 
increased potential for exchange of information, support and advice. 
2.2.1 Why community pharmacy is well placed to provide support in this area 
Community pharmacy is well placed to provide support for people in the community for 
many reasons. The general public perceive CPs to be medicine experts, trustworthy and 
reliable advisors,27 who encourage engagement and they are often a familiar face, known to 
many in the community.28 The community pharmacy is often the first point of contact in the 
health care system, and CPs are generally found to be the most easily accessible primary 
health care professionals. There is no requirement for an appointment with the CP and they 
can usually be seen without much delay, and certainly on the same day. CPs typically offer 
an extensive range of services, many of which are offered free of charge. Community 
pharmacies also offer extended trading hours, including weekends and public holidays. They 
are generally situated in main shopping areas, in both urban and rural localities, increasing 
their accessibility.  
2.3 Community Pharmacists and Primary Mental Health Care 
2.3.1 Community pharmacist role: internationally  
Historically, the dispensing of prescribed medication has been the well-recognised domain 
of the CP, accompanied by the retail sales of non-prescription pharmaceutical products. 
However, in the United States of America in the 1990s revolutionary changes occurred with 
the development of a new concept in pharmacy known as Pharmaceutical Care.  
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This changed the pharmacists’ role and orientation from being just the supplier of the 
medicine to include the supply of clinical pharmacy services aimed at improving the 
outcome for patients.  
Hepler and Strand, the founders of this new concept, defined Pharmaceutical Care as being: 
“The responsible provision of drug therapy for the purpose of achieving definite outcomes 
that improves a patient’s quality of life.” 29p539  
This involves cooperation between CPs, patients and other health professionals with the aim 
of producing specific therapeutic outcomes for the patient. 
For their generalised role in primary health care, the World Health Organization (WHO) and 
the International Pharmaceutical Federation (FIP) have together promoted increased 
pharmacist involvement in patient care, and providing more to the patient than just 
medicine dispensing. They have described pharmacists’ general role as being “a caregiver, 
communicator, decision-maker, teacher, life-long learner, leader and manager”.27 p16 Further 
advancements of pharmacist services offered to patients, known as cognitive services, are 
defined as “the use of specialised knowledge by pharmacists for promoting safe and 
effective use of the medicines”.30 p245 
Community pharmacists have long since been recognised as drug experts, with their 
expertise in identifying the appropriateness of drugs, drug interactions and avoiding 
therapeutic problems in both physical and mental health care.31 The CP role includes 
ensuring effective, efficient and safe use of medicines.32 CPs have been shown to have a role 
in drug monitoring, treatment recommendations, patient and provider education and drug 
therapeutic management.33,34 This is in addition to the promotion of medication adherence, 
reinforcement of primary prevention, and health promotion and lifestyle modification 
activities.35 
2.3.1.1 Drug treatment in primary mental health care 
To achieve optimal results from medication, the prescribed drug needs to be taken at the 
appropriate dosage, and treatment is to be administered for the prescribed length of time. 
Despite the availability of medication for the treatment of mental illness, adherence to 
prescribed medication is recognised to be of concern.36 Patients often need help and 
guidance from CPs on a regular basis to adhere to treatment to achieve better patient 
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outcomes.37 In mental illness, without continued drug treatment, prior levels of functioning 
may not be restored and there may be increased risk of relapse and recurrence.28,38,39 Some 
available statistics have shown the rate of recurrence and relapse in depression to be 
particularly high, being up to 80 percent. These statistics also showed treatment failure 
rates in the 40-60 percent range, and 20 percent of patients remain without adequate 
treatment for their mental health care.40 Statistics from the Netherlands show that 
approximately one in four patients with primary mental health conditions did not fill original 
prescriptions or did not continue taking their medication for longer than two weeks, and 
more than half the patients discontinued treatment within six months.41,42 A study in Canada 
showed similar results but estimated 45-60 percent of patients stopped their antidepressant 
drug treatment within an even shorter space of time, being within the first three months, 
regardless of the fact that at least eight months use is recommended by the clinical practice 
guidelines.43 The nonadherence to antidepressant therapy was also found to be a major 
challenge in the United States, with rates of nonadherence of antidepressants being found 
to be 29-40 percent in the older adult population group.44  
2.3.1.2 Community pharmacists and their role in patient adherence in mental health care 
Despite limited research being carried out on CPs in mental health, a small number of 
studies are available that show the effectiveness of CPs in supporting improved patient 
adherence to antidepressants. In 2014 and 2015, research carried out by Rubio-Valera et al 
and Hattingh et al, respectively identified some systematic reviews and a number of 
randomised controlled trials (RCTs) which showed that pharmacists interventions were 
effective in improving patient adherence in their antidepressant treatment.35,36 However, it 
was noted by Hattingh et al in an Australian study that the large majority of RCTs only 
involved patients that were newly initiated on antidepressants and were at the beginning of 
their treatment. Hattingh et al noted the CPs intervention was not carried out for the whole 
length of the patients’ mental health treatment, even if treatment was long term. Also, it 
was mentioned that the focus of the studies was on adherence as the primary outcome and 
not patient clinical improvement or patient outcome. More recent evidence from Readdean, 
Heueu and Parrott in a systematic review in 2018 showed that patients were two-and-a-half 
times more likely to adhere to their antidepressant medication when there was CP 
intervention.45 This latter study, however, showed that in terms of symptomology, CP 
intervention showed similar levels of clinical improvement from groups without CP 
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involvement, in almost all cases. This was in contrast to research by Ho et al46 who 
demonstrated in a systematic review that CP intervention improved symptomology, 
showing that there was a strong connection between adherence to antidepressants and 
improved symptoms. This may be explained by the fact that research undertaken by Ho et al 
included studies that had a longer follow-up period of greater than six months. This is 
thought to have contributed to the improved clinical symptoms, which were not seen in 
research of lesser duration. 
A systematic review from Auckland University published in 2018, looked into worldwide 
literature of CP led interventions to look for improved patient adherence in a number of 
medical conditions, including depression. It was found that while there was improved 
patient adherence and health outcome in blood pressure control, cholesterol management, 
COPD and asthma control, it was not seen with diabetes or depression. However, this study 
may have limitations due to examining only three depression studies. It also identified a 
number of barriers to CPs effectiveness, including CPs being their own barrier and the need 
to look into education and other intervention components to investigate their impact on 
patient adherence.47 
2.3.1.3 CPs and their role in medication reviews, support, monitoring, usage and efficacy 
As part of pharmaceutical care and clinical pharmacy services, medication reviews 
conducted by CPs aim to optimise the use of medicines and reduce the use of potentially 
inappropriate medicines. This has been shown in the systematic review from Bell et al in 
2005 which showed that CP conducted medication reviews could reduce the number of 
potentially inappropriate medications prescribed to those in the high risk medication group 
for mental illness, including those prescribed for primary mental health conditions.37 Gisev 
et al48 in 2010 also found similar results with the work by CPs for patients in community 
mental health teams. The recommendations by CPs from medication reviews were 
appropriate to optimise drug therapy and also to improve clinical outcomes.  
Research in Australia with off-site medication reviews in residential aged care facilities, 
known as Residential Medication Management Review and medication reviews in the 
patients home called Home Medicine Review showed that pharmacists were effective in 
medication reviews, by reducing exposure to potentially harmful drug reactions, including 
some commonly used drugs in mental health care.35 
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Research undertaken by McMillan et al49 in Australia to trial a new mental health 
medication support service in community pharmacy was published in 2018. The research 
showed that trained CPs were able to provide medication support services to mental health 
patients with depression or anxiety, to achieve improved outcomes. The support services 
made significant improvements for overall perceptions of illness, concerns about medication 
and global satisfaction with medication as well as an increase in adherence. The patients 
acknowledged that they thought it was a valuable service and it resulted in the patients 
being more motivated in managing their mental illness and also being more confident and 
able.  
In comparison, the monitoring of medication usage and the efficacy of antidepressant 
medication in mental health care has not been well demonstrated by CPs. Nor is there much 
evidence available, although it is a service that has been suggested by community pharmacy 
leaders in Canada.43 The difficulties involved have been attributed to the absence of 
assessment tools or guidelines to assess responses to medication by CPs when dealing with 
mild to moderate depression or anxiety.  
2.3.1.4 Community pharmacists’ educational and supportive roles 
Community pharmacists are well recognised as a resource for providing general health 
information to the individual, their families and carers. They are known to be good 
intermediaries supplementing, sometimes collaborating with, explaining and reinforcing 
new medication and medication changes and expanding on information not provided by the 
patients’ GP.50 Due to their training and specialist knowledge they are also able to provide 
information to other allied health professionals.43,51 However, in dealing with mental health 
care, Chong et al in a systematic review investigating adherence to antidepressant 
medication found that education, when given by CPs to patients in isolation, was ineffective 
and that it was necessary to have accompanying interventional activities for there to be 
improved effect. These included telephone follow-ups and monitoring, pharmacy visits, 
behavioural prevention plans, psychotherapy, and pharmacy repeats and checks for 
improved patient outcomes.52 
2.3.1.5 Community pharmacists’ role in informed choice and shared decision making  
Evidence available now suggests that shared decision making between the patient and the 
health professional produces better outcomes, rather than trying to ‘make’ patients adhere 
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to prescribed medication.53 CPs can help patients become fully informed regarding their 
antidepressant medication, so that shared decisions result in better treatment outcomes. To 
help in this process, education given by telephone monitoring 54and video-conferencing55 as 
well as motivational interviewing36 has been used by some CPs and has been seen to be of 
value.  
2.3.1.6 Community pharmacists’ supporting role and non-medication related roles 
A supporting role also exists for community pharmacy which includes the provision of a safe 
place for those with mental illness and to provide ongoing emotional and social support. 
The formation of strong relationships between CPs and people with mental illness helps to 
build trust, remove stigma and increase patients’ own self-esteem, confidence and well-
being so they are better able to take care of themselves.28 
Other non-medication related interventions from CPs include health system navigation, 
making referrals to community groups and other health care professionals and triaging as 
appropriate. This can be especially important in times of mental health crisis.56 
2.3.1.7 Future roles of community pharmacists in primary mental health care 
In the past decade, there have been moves from government health policy makers, leaders 
in health education, and professional pharmacy associations toward increased collaboration 
and closer connections between CPs with other primary health care providers, such as GPs 
and nurses in general practice and a push for integration into multidisciplinary primary 
health care teams.16,35,43,57 Working as part of a multidisciplinary team can lead to the 
opportunity for CPs to be more proactive in their medication management and to work in 
extended roles where they can operate in a collaborative model of care, sharing their 
knowledge of medication and the patient with the other members of the team.16 This may 
involve discussion between CPs and GPs, of the actual and potential medication-related 
problems of individual patients. Also included can be strategies for optimisation, individual 
medication regimens and identification of polypharmacy. This can lead to significant 
improvements in pharmacotherapy and better overall health care, in all aspects of both 
physical and mental health. In a recent systematic review published in 2020, it was found 
that when pharmacists were part of collaborative teams for mental health care, they were 
effective at improving the outcomes for patients.58 
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Other possible CP services include the role of pharmacist prescriber collaborating in mental 
health care. It was acknowledged that collaborative prescribing is a legitimate role for 
appropriately trained pharmacists in mental health care. 59 
A further role for CPs is in the area of depression screening. There are a number of reasons 
that CPs are ideally placed to do this including their accessibility, their training and their 
recognition of symptoms and knowledge of availability of services. With depression 
screening and risk assessment, depression may be identified earlier and lead to referral and 
care sooner. 
The roles of CPs internationally are compared with those of New Zealand CPs in the 
following section. 
2.3.2 Community pharmacists’ role: New Zealand 
Research was carried out by Crump et al.60 in New Zealand in 2008 and was published in 
2011, aimed at identifying services provided by CPs specifically to people with mental 
illness. Qualitative interviews were carried out with nine CPs and it was found that while 
particular medication review and therapeutic assessment services were available to 
patients, there were also other considerations to what CPs did. They found that CPs formed 
relationships, offered more than just medicinal advice and ensured that patients received 
their medication, despite not always having funds to pay. As part of provision of medicines 
there was patient-focused care, family involvement, education, psychological support, 
referrals and culturally appropriate practice.60 Relationship building and having a trusting 
relationship between patient and pharmacist was found to be an essential part of the CP 
role in the delivery of successful care.60 Service delivery packages included compliance 
packaging, close control dispensing, home deliveries, home visits and support for mental 
health residential facilities. These varied depending on funding, availability of resources and 
the requirements of the community. 
Community pharmacy services provided by New Zealand CPs were investigated further in 
2014 by Smith et al and published in 2018.61 This resulted in a comprehensive list of all 
services provided by CPs, funded and non-funded, and identified services offered that are 
more clinically orientated and patient centred. It showed that the top two most frequently 
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provided services have no public funding attached; these being the provision of education 
and advice on prescription medicines and on over the counter (OTC) products.61  
There has been direct nationwide funding to CPs for the administration of the mental health 
drug clozapine, though this has been the only funded mental health service specified. 
However, there is one District Health Board (DHB) funded pharmacy service, outside of 
national funding, being for the particular antidepressants, Selective Serotonin Re-uptake 
Inhibitors (SSRIs). This is counselling for people when they are initiated on SSRI 
antidepressants, and funding is available through CPs working on an individual basis with 
their local DHB.62 
2.4 Factors Influencing Provision of Mental Health Care by Community Pharmacist 
Within community pharmacies there can be many variations of services offered for those 
with primary mental health conditions. Evidence suggests that a number of factors influence 
the actions of CPs, some specific to the pharmacy practice environment and patients and 
others CP dependent.63 The following list of influencing factors is discussed in turn: 
1. Stigma, education, attitude and confidence 
2. Organisational culture, staffing, time and funding 
3. Confidentiality, privacy and trust 
4. Assessment tools and guidelines  
5. Relationship with other health care professionals.  
 
2.4.1 Stigma, education, attitude and confidence 
Within pharmacies and many other areas of health care, there has been an awareness of 
the presence of stigma in relation to mental health, and over time there have been moves 
made by CPs to lessen this.64 
Research carried out on stigma defines it as consisting of the following three things: 
1. Lack of knowledge, misinformation or ignorance 
2. Negative attitude or prejudice and shame 
3. Behaviour or discrimination issues.35,65 
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Community pharmacists’ provision of services in mental illness may be influenced by and 
linked with stigma, education, beliefs and attitudes and CP confidence levels.66 In a 
community pharmacy situation, people may feel stigmatised with negative attitudes 
directed towards them or they may be treated differently when their diagnosis of mental 
health becomes known. This stigma can result in social marginalisation, a reduction in 
patients seeking help, undertreatment, and also nonadherence to treatments resulting in 
poor treatment outcomes and shorter lifespans.35,67,68There is also an added barrier to 
recovery due to negative effects of stigma on social status, self-esteem and social 
networking.65 
Stigma can be from multiple sources: the patient themselves, the general public, and any 
member of the health care team, including GPs and CPs.68 A small number of studies 
investigating the attitudes of CPs towards people with mental health disorders found that 
CPs generally felt they had a positive attitude towards people with mental health disorders. 
Despite this, the research also found that the CPs provided more pharmacy services to those 
with physical illness as opposed to those with mental illness.68,70 Further studies showed 
that decreased levels of confidence and comfort could be barriers to CPs providing services 
to patients with mental illness.65,66,71 
Barriers to CPs’ provision of mental health services in some cases were due to a perceived 
lack of, or inadequate training or education, at both student level and as experienced CPs. 
More education in mental health can improve attitude, knowledge and confidence in 
mental health and the prevention of stigma.66,72 CPs were found to be much more confident 
in the more traditional roles of assessing patient knowledge of medications and adverse 
effects than they were with the provision of specific services and assessing the medication-
related therapeutic outcomes and consulting with GPs.65 An Australian study by O’Reilly, Bell 
and Chen73 showed that despite CPs showing a high degree of mental health literacy, they 
concluded that pharmacists should be aware that their attitude toward mental illness can 
impact on the patient care they provide.  
Certain aspects or characteristics of CPs showed an effect on their attitudes towards mental 
health. Older pharmacists endorsed a more negative attitude, as did pharmacists in rural 
areas.74 It was also seen that there were more challenges with stigma shown by CPs in 
smaller communities.65 Neither gender or personal experience with depression were seen to 
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have an effect on CPs’ attitudes to mental health care in the study by Scheerder.74 However 
other research has found the opposite, and CPs who had personal experiences with mental 
illness were more confident and comfortable dealing with patients with mental illness than 
those who had not.65 
In some cases CPs believed that patients were reluctant to discuss depression with them. In 
qualitative studies by Guillaumie75 and by Scheerder74 it was found that patients were felt to 
have negative attitudes towards medication, with antidepressant medication being thought 
of as more harmful than helpful, addictive and ineffective, or weight gaining and lifelong. 
CPs felt there may also be negative attitudes from patients themselves regarding mental 
illness and the need for antidepressant drug treatment with feelings of guilt or 
embarrassment about their mental illness diagnosis.75 
All these issues can and do affect how CPs deal with their patients and need to be evaluated 
to know the impact they have upon mental health patients. 
2.4.2 Work environment (organisational culture, staffing, time and funding) 
2.4.2.1 Organisational culture 
Organisational culture is the culture that exists in a particular organisation or workplace, 
and describes the values and behaviours of the organisation or in general the way things are 
done there. In community pharmacy it is the combination of the CPs and individual staff 
members and their attitudes, beliefs and values and how they act collectively as a 
whole.35,76 While organisational culture has not been comprehensively studied in pharmacy 
and its effect on mental health services are largely unknown, it can have an effect on the 
provision of primary mental health services due to the way pharmacy staff approach mental 
health care and the patients that it involves. In a community pharmacy the organisational 
culture includes both the business or retail side of the organisation as well as the 
professional pharmacy services aspect. However, the combined nature of community 
pharmacy, being a retail business and depending on sales for viability, but also offering 
professional pharmacy advice free of charge, are diametrically opposing views, and can be a 
difficult environment for staff to comprehend and to work in.35 
2.4.2.2 Staffing, time and funding  
Remuneration of community pharmacy has historically been based on the dispensing of 
prescriptions and money that is raised through retail sales. Pharmacy is the only health 
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profession that is reimbursed for the sale of a product and there is no direct payment for 
the actual services provided.32 However, with the emergence of patient-centred services in 
the last few decades there has been the need to introduce a new and adequate 
remuneration model for payment. This has been limited to date and while remuneration 
within community pharmacies continues to be aimed at reimbursing dispensing services, it 
will not encourage CPs to provide unfunded patient centred care.32,35,77 With the emphasis 
on funded services, researchers believe clinical services that are unfunded will not have the 
priority of the staff. Unless funding for clinical services becomes available, appropriate levels 
of staff to support clinical services cannot be maintained and an appropriate amount of time 
will not be available to provide these services. Having insufficient time is one of the most 
often quoted reasons that CPs offer as being a factor in provision of clinical pharmacy 
services30,60,68-70 The lack of time can thus be seen to be linked with lack of staff or resources 
for staff, and in turn linked to lack of funding.60 
2.4.3 Confidentiality, privacy and trust 
Privacy and confidentiality within the space of a busy community pharmacy can be difficult 
to achieve and the lack of privacy can significantly impair some CPs’ abilities to develop 
relationships with patients.30,60,68-70 In a quantitative study carried out by Black78 with 
patients in Canada in 2009, less than 60 percent in the study population reported that they 
were comfortable speaking about their medication for mental illness with CPs, and Black felt 
this could be due to lack of privacy or lack of availability of a consulting area. The need for 
privacy for patients when receiving pharmacy services from CPs has been a concern27 and 
facilities that can provide privacy between CP and the patient has been recognised as good 
pharmacy practice. This situation has been reviewed by CPs, with pharmacies now providing 
a private area for consultations to take place, in New Zealand and internationally79-81 
2.4.4 Assessment tools and guidelines 
The treatment in mental health care is unlike physical conditions such as diabetes, 
hypercholesterolaemia and hypertension, all of which have direct physical assessment tools 
easily available, for a measurable outcome. Guillaumie75noted in 2015 that the absence of 
such a tool for mental health care prevented CPs from being able to easily monitor the 
effectiveness of treatment in mental health treatment and that there is a need for 
guidelines to aid the monitoring and assessment of patients. Research by Hattingh et al36 in 
19 
 
2016 similarly noted that research had focused on adherence as the key outcome rather 
than comprehensive assessment, despite the fact that clinical improvement is not mediated 
solely or directly through adherence to medication. Adherence may have been followed up 
due to difficulties in appropriately assessing mental health treatment and improvements 
and the lack of an easily accessible assessment tool for CPs to better detect and intervene in 
mental health treatment. 
2.4.5 Relationship with other health care professionals 
Community pharmacists may be working in varying degrees of collaboration with other 
health care workers and this can affect their effectiveness and the services that they provide 
to patients with mental health needs. Patient medication management can be hindered by 
limited or poor information flow about the patient between the GP and CP.50  If able to work 
in close collaboration with GPs, CPs can provide much more effective individualised 
treatment and patient counselling of patients than if they are working in isolation.75 It is also 
thought that GPs and other members of the primary or the mental health team may not be 
fully aware of the full extent of the knowledge or the capabilities of a CP, or how CPs can 
support the patient.60 GPs and medical practitioners may not know what to expect from CPs, 
and lack awareness of CPs’ level of training and knowledge.60 
Despite some research showing a preference for CPs to be integral members of the health 
care team, barriers and interprofessional issues by GPs show they are not always receptive 
to CPs’ involvement. Professional competitiveness and encroachment to established 
practices were some identified concerns. However, this research by Hughes and McCann82 
was carried out almost two decades ago and studies carried out more recently indicate 
otherwise, with GPs now being more receptive to CPs.75 A study by Chong, Aslani and Chen 
in 201383 has highlighted changes that need to be made in all professional groups to 
promote interprofessional collaboration. However, resistance has also been seen to come 
from within the pharmacy profession itself. The research of Chong et al84 also showed that 
there were some CPs who regarded the provision of primary mental health care as being the 
jurisdiction of the physician and not the pharmacist.84 This piece of research set about to 
evaluate the counselling practice of CPs in regard to patient adherence to antidepressants. 
They found that some CPs tended to refer patients back to the GP and there was some 
discomfort seen by CPs at crossing interprofessional boundaries. This was also seen in a 
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study carried out by Landers in 2002.85 This could have quite an effect on the CPs role, as 
being part of a multidisciplinary collaborative team, if they see their role as deferring to the 
GP and not acting in their own right as the patients advocate regarding patient treatment.  
2.5 Literature Review Summary 
In addition to their historical medication supply role, CPs have been shown to provide a 
range of clinical pharmacy services and support, advising and advocating for people with 
both physical and mental health care needs. A great deal of research supports CPs’ 
involvement in the care of patients with physical health conditions such as diabetes, 
cardiovascular and respiratory diseases. Despite the high numbers of people that are 
affected by mental illness globally, research to date on the CPs’ involvement in primary 
mental health care is limited. The role of CPs in mental health care and the CPs’ view of their 






3. AIMS AND OBJECTIVES 
Aim: To explore community pharmacists’ perceptions of their role in primary mental health 
care.  
This aim can be achieved by means of the following objectives: 
1. To explore the types of primary mental health services that community pharmacists 
currently deliver 
2. To explore what primary mental health services community pharmacists think they 
should/could deliver and what they would like to deliver 
3. To explore the barriers that community pharmacists feel prevent them from 
delivering these primary mental health services and finding out what would facilitate 








This chapter describes the methodology used in this research. It begins with a discussion of 
the chosen methodological approach, followed by the data collection and research sampling 
strategy. The data analysis processes used are then outlined. Methods to ensure quality of 
the research conclude the chapter.  
4.1 Methodological Approach: The Theoretical Framework  
In carrying out research, it has been stated by Creswell86 that there are three different 
frameworks or paradigms that can be undertaken, these being quantitative analysis, 
qualitative analysis, or mixed methods (which is a combination of both quantitative and 
qualitative analysis). The qualitative framework was the chosen methodology for this 
research, as it was the best fit for the research topic where little is known about New 
Zealand community pharmacists’ (CPs’) perceptions of their role in primary mental health 
care. In delving into the area of attitudes, thoughts and ideas of CPs, qualitative analysis 
allows views and experiences of a small number of individuals to be examined in depth, in 
the search for meaning and understanding.87 Qualitative methods can identify people’s 
ideas and thoughts in their own words rather than that of the researcher and also discovers 
a person’s individual understanding of the situation.88 Qualitative analysis is also particularly 
useful in the exploration of social and behavioural issues related to health care,89 which is 
the area of research under investigation. From the data collected, thematic analysis was 
deemed an appropriate method of interpretation, where themes were identified to inform a 
theoretical understanding of the research question involved.89 
4.2 Data Collection 
4.2.1 Data collection methods 
Interviewing Face to Face: Within qualitative analysis, various methods for data collection 
are available. One such method is individual face-to-face interviewing, which has been 
chosen for this research. The face-to-face interviewing method has been seen to be the 
ideal way to collect interview data.89 It allows the researcher to build rapport and a 
relationship with the participant and delve into participant experiences and perspectives, 
thus providing rich and detailed data. Interviewing is flexible and even with smaller sample 
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sizes, sufficient data can be generated.89 It can produce thoughtful, thorough, and possibly 
unexpected data as well as allowing the research question to be addressed.89 There are 
disadvantages to face-to-face interviewing, which includes the additional costs and time 
involved in travelling.90 However, with approximately half of the participants interviewed 
living in the local area and with judicious planning of trips out of the area, face-to-face 
interviewing was possible for this study. 
Focus Groups and Qualitative Surveys: The use of focus groups was considered as an option 
for data collection, but despite the potential for producing substantial information from 
numerous people in a relatively short time frame,91 there can be confidentiality and 
anonymity problems as well as ethical and cultural concerns when groups of people are 
involved. Answers in a group forum may be dominated by some individuals or may not 
always be the real responses that would have been elucidated if responding individually.91 
Qualitative surveys, another form of qualitative analysis, though not interactive, can 
produce larger amounts of meaningful data, reasonably cheaply, with the use of series of 
open-ended questions. However, with qualitative surveys the data is self-administered and 
without the presence of the researcher may not lead to new information, as participants are 
not able to be questioned, probed and extended, for richer more meaningful data.89 
4.2.2 Interview type 
Semi-structured interviews were chosen as being able to best answer the research question 
on CPs’ perception of their role in primary mental health care. The questions, compiled in an 
interview schedule, were open ended and as non-directive as possible, allowing participants 
to talk openly and frankly in their own fashion.89 The questions were not strictly adhered to, 
allowing the interview to flow and proceed in the direction dictated by the participant. This 
also facilitated the ability to probe more deeply and achieve greater in-depth knowledge 
about the situation.89 New concepts that may not have been anticipated could be followed 
up, allowing for a greater number of themes and concepts to be investigated. This was 
chosen in preference to in-depth interviewing which usually has a focus on a much smaller 
topic, uses fewer questions and seeks very detailed descriptions.87 
4.2.3 Data recording and transcribing 
The data generated from the interviews were digitally recorded, then professionally 
transcribed verbatim. Consent for recording was sought before the interview and agreed 
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upon at the time of the interview. The first interview was transcribed by the researcher and 
the remaining fourteen interviews were transcribed by a professional transcriber. With the 
interviews all being digitally recorded, it was not necessary to manually write down 
interviewee responses, minimising any hold-ups in the interviews and allowing the 
interviews to flow freely. The interviews transcribed verbatim were then used to produce 
the data set. 
4.2.4 Interview process 
Of the fifteen interviews, fourteen were carried out by the researcher and one by an 
appropriately experienced researcher. This interview occurred due to the availability of both 
the researcher and participant in a remote location, at the same location on the same day. 
The pharmacy technician was present at the same time, and also contributed to the 
interview.  
4.2.5 In the field 
The researcher took field notes for all interviews, which included information about the 
setting and participant and researcher interaction. This added rigour to the process as these 
can affect the interpretation of the data.89,92 
4.2.6 Interview schedule 
The interview schedule (Appendix C) was focused by the research aims and objectives 
detailed in Chapter 3. It has the full list of possible questions and all the necessary 
information to be remembered in the interview setting.93 The questions were initially 
compiled by the researcher and modified in discussion with the supervisory team. Questions 
were informed by the researcher’s experience when practising in community pharmacy as 
well as questions raised from literature readings and during pharmacy postgraduate studies. 
The questions were added to and modified as the interviews progressed, showing an 
iterative process 94 formulating specific questions for some specific pharmacy situations. 
Questions were styled to be open ended, neutral, sensitive, clear and respectful. 
Within the interview schedule the following topics were covered: 
1. General pharmacy background 
2. Mental health specific to pharmacy location 




4. Alternative care, e.g. over the counter (OTC), lifestyle, psychologists, counselling, 
cognitive behaviour therapy 
5. Barriers and facilitators to provision of mental health care 
6. Collaborative care. 
4.2.7 Pilot interview 
Before the first interview with a CP, a pilot interview took place with an experienced senior 
researcher from within the university. This trial of the interview schedule led to some 
changes in the questions and allowed for testing of the recording equipment and timing 
requirements for questioning. 
4.3 Research Sampling Strategy 
The research sampling strategy is developed to identify specific groups of people who either 
possess characteristics or live in circumstances that relate to the phenomenon being 
studied,92 being able to provide rich accounts of their experiences and contribute some 
meaning to the research question.89,94 To investigate CPs’ perceptions of their role in 
primary mental health care, this research required pharmacists who were currently 
employed in community pharmacy in New Zealand and included those who deal with 
patients that have primary mental health medication needs. 
4.3.1 Research sampling techniques: convenience and purposive sampling 
The use of several different sampling techniques allowed for individuals to be selected that 
were appropriate for this research. The two sampling techniques used were convenience 
and purposive sampling.90,94 Convenience sampling used participants willing and available to 
participate. They may or may not have a specific interest in primary mental health, but were 
prepared to provide their thoughts and experiences in this area of community pharmacy. 
The availability of these CPs within the vicinity of the researcher was of benefit for the 
research to occur. Purposive sampling was used to deliberately choose specific participants 
for crucial information they may have. They are information rich and can offer in-depth 
understanding and insights, and not just empirical generalisations.95 Within purposive 
sampling there is also the ability for extreme or deviant case sampling, choosing cases that 
are extreme in some ways. This is also known as outlier sampling as it involves selecting 
cases near the ends of the distribution of cases of interest, and allows for comparison with 
others that are not so extreme.95 In this research there were a small number of CPs that fell 
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into this category, as they had quite large numbers of patients that received primary mental 
health medication, compared to the other CPs and their sites of practice. 
4.3.2 Research sample size 
Sample size in qualitative analysis typically focuses on relatively small numbers, selected 
meaningfully and strategically for information-rich data.89 No set formula is applied rigidly to 
determine the sample size. Rather it is dependent upon the depth of the research and if 
there is enough data collected to allow the research question to be thoroughly addressed or 
if data saturation has been reached. This occurs when no new themes emerge.95 The sample 
size for this research was proposed to be fifteen interviewees, as for a narrow research 
question, a sample size between six and twelve is said to be potentially adequate and if the 
research addresses a fairly specific research question it has been suggested that after 
analysis of fifteen interviews, there is generally little new data.95 
4.3.3 Recruitment 
The convenience sampling method involved the distribution of an initial individual email to 
all pharmacists in the Wellington Branch of the Pharmaceutical Society of New Zealand 
(PSNZ), i.e. the local branch for the researcher. This email is included in Appendix D and was 
sent with the consent of the Chief Executive of PSNZ. This was done to identify local 
pharmacists who were interested in participating in a study about CPs’ perception of their 
role in primary mental health care. Essential inclusion requirements were New Zealand 
registered pharmacists who were currently working in community pharmacy. Therefore, all 
hospital pharmacists were eliminated from the study. This resulted in eight local CPs who 
volunteered to be interviewed. They were then emailed an information sheet (Appendix E) 
with more details regarding the interview. They were given an opportunity to ask general 
questions about the study before an interview time and place was determined, and if they 
still wanted participate. All eight of the CPs were keen to be interviewed.  
Purposive sampling was used to recruit the remaining participants to be interviewed and a 
further eight CPs were approached. This was done in collaboration with the supervisory 
team. It was decided that CPs from both the North and South Island should be interviewed 
to gather diversity. There were several Auckland CPs that were purposively targeted, being 
based in the highest density population area of New Zealand and with the probability of 
insight and knowledge in the primary mental health arena. A small number of CPs in other 
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areas of New Zealand were purposively chosen due to their special interest in primary 
mental health care and the large number of patients with mental health issues that they 
dealt with on a regular basis. One Christchurch CP was chosen due to the higher stresses 
and anxiety that have occurred since the Christchurch earthquakes in 2011. The remaining 
CPs were chosen due to their expressed interest in the primary mental health area. This 
resulted in seven CPs agreeing to be interviewed. There was one refusal due to time 
commitments.  
Contact was made with all fifteen participants and they were interviewed in the period 
between November 2016 and September 2017. Before the interview all participants were 
given a consent form (Appendix F) to review and then sign if they were happy to take part in 
the research interview. 
4.3.4 Demographic data  
All the participants interviewed had demographic information collected using the 
Demographics Form (Appendix G) and this was done on completion of the interview.  
4.4 Analysis 
For analysis of data, thematic analysis was undertaken, which involved coding and then 
identifying themes and patterns from codes. Initially, the audiotaped interviews were 
listened to and the transcripts read to ensure they were accurate and to become familiar 
with the data. This was done multiple times before the actual data analysis began. 
4.4.1 Data analysis 
The method of data analysis used for this research was the thematic analysis (TA) approach, 
being a pattern-based method. It uses a systematic approach for identifying, analysing, and 
reporting common patterns of data or themes, within the given data set.96,97 
Data analysis was carried out using the ‘complete coding’ technique where all data relevant 
to the research question was manually coded without being selective of any particular idea 
or phenomenon. Each code or word or brief phrase that captured the essence of why a 
particular piece of data could be useful was identified.89 Coded data were then collated, 
looking for larger patterns across the data, or themes. These themes captured something 
important from the data that related to the research question, with the codes combining to 
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form the themes.89 Themes had a central organising concept and captured the most salient 
patterns in the data set. Themes put together then more fully described a phenomenon.98 
4.4.2 Phases for thematic analysis 
The following six phases were carried out for thematic analysis.  
Table 4.1: Phases for thematic analysis* 
Phase 1:  
 
Familiarisation with the data by hearing the recordings and 
reading the transcripts multiple times 
Phase 2:  Generation of initial codes from all the data 
 
Phase 3:  
 
Search for themes. Relationships between codes were identified 
and initial themes were developed in discussion with 
supervisors 
Phase 4:  
 
Review of final themes, agreed between the researcher and the 
supervisory team 
Phase 5:  
 
Naming and defining themes, agreed between the researcher 
and supervisory team 
Phase 6: Write up 
 
*Adapted from reference (102) 
4.5 Methods for Quality 
The use of qualitative research to study the experiences of individuals, to find meaning and 
understanding is said to be an appropriate tool.95 With quantitative and qualitative research 
being so fundamentally different, the methods for determining the quality of qualitative 
research cannot reasonably be the same as that of quantitative research. What is regarded 
as ideal in quantitative research such as the objectivity of the researcher and the collection 
of information without any input from the researcher is not regarded as being an imperative 
part of qualitative research.99 For this qualitative research, validity, reflexivity, bias, rigour 
and data accuracy will be discussed. 
Validity is when a piece of research can show what it claims.89 A strategy that was used in 
this research to promote validity is the provision of particularly detailed descriptions, so that 
any interested parties can verify the interpretations.86 Two techniques for reliability include 
first, the provision of a detailed account of the aims and objectives of the research, the role 
of the researcher and the selection of the participants. Second, data collection and analysis 
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strategies have been reported in detail, and methods used are provided accurately and 
clearly, which also helps to ensure reliability.86 
Reflexivity and researcher bias: Reflexivity has an important role in qualitative analysis as it 
deals with the influence that comes from the researcher’s own perspective and views on the 
topic, whether intentional or not.99 Because the researcher also has an existing knowledge 
of their participants, they have a greater understanding of the participants’ situation and 
the researcher can construct meaning that may have been lost to those without this prior 
knowledge and understanding.99 Any finding by the researcher in qualitative analysis is the 
product of the researcher’s interpretation, and subjectivity can be considered an 
advantage99 and also as a strength.89 Due to this subjectivity, bias is not regarded in the 
same way as it is in quantitative analysis. It is still important to mention researcher bias, 
which can be in evidence during all stages of the research, the participants chosen, the data 
collection instrument, development of the questions, during the interview and during data 
analysis. Social desirability bias may also be in evidence, which is bias displayed by 
participants who wish to be seen in a favourable light by the researcher and may therefore 
not speak completely truthfully.  
Rigour of the research was contributed to by the diversity between the supervisors, with 
one supervisor having a pharmacy background and the other having a related health 
background. This provided a multi-disciplinary perspective, helped prevent pharmacist bias 
and created balance in the research team. Both supervisors attended all meetings which 
were held regularly throughout the research. When either supervisor was not able to attend 
in person, contact was made via video-conferencing. 
Data accuracy was assured by all interviews being audio-recorded and all transcribed 
verbatim by the same transcriber, bar one interview which was transcribed by the 
researcher. This allowed for consistency in the transcribing. To ensure accuracy of the data 
all audio-recordings and transcripts were listened to and read multiple times, before data 
was coded and analysed. Transcripts were also available to the interviewees, so they had an 
opportunity to ensure that the transcripts were a true representation of their interview and 




All data were reviewed separately by the researcher and the two supervisors for 
independent assessment before coding and thematic analysis. This method of triangulation, 
known as analyst or investigator triangulation, uses multiple analysts and their comparisons 
then helps to lessen potential bias from just one person doing all the data collection. It 
allows for more direct assessment of the reliability and validity of the collected data. Being 
able to discuss and compare findings provides a check on selective perception and 
interpretive bias, by providing multiple observations and conclusions.101,102 Quotes were 
used directly from the transcripts to illustrate and validate the themes, which ensures the 
themes are trustworthy and are a genuine part of the research data and not pre-determined 
by the researcher.102 Field notes were taken for all interviews, so that any influencing factors 
could be recorded and accounted for. 
All these methods have been incorporated in this study to ensure quality within this 
research.  
4.6 Ethics Approval 
This research was granted ethics approval from the University of Otago Human Ethics 
Committee Category B (Appendix H). Approval was also received from the Ngai Tahu 
Research Consultation Committee (Appendix I), with the request that the results of the 
research be disseminated to Māori health organisations and to the Māori Pharmacists 








This chapter describes the results obtained from the interviews carried out during this 
study. It includes a table of the participant demographics and a map of New Zealand with 
the locations of the community pharmacists (CPs) that were interviewed. CPs’ beliefs 
regarding their role in providing primary mental health care and contributing factors to the 
provision of these services have been identified together with direct illustrative quotes. 
5.1 Participants and Locations 
The research involved fifteen CPs in New Zealand, located from Whangarei in the North 
Island to Christchurch in the South Island. Included was representation from Auckland, the 
east coast of the North Island, Kapiti Coast, Wellington, Nelson and Marlborough district, 
and participants further south in the South Island. 
Participants were interviewed at their most convenient site, which resulted in interviews 
being held in community pharmacies, private homes, cafes, a University of Otago Wellington 
meeting room and Pharmaceutical Society of New Zealand premises. 
The length of the interviews varied, and ranged between forty to ninety minutes each. 
5.2 Response Rate 
A Wellington regional pharmacy group email was distributed to 468 registered pharmacists 
to find interested participants in the area. This was a reasonably large group and not all 
those that received the email were eligible to participate, i.e. emails were sent out to all 
practising and non-practising pharmacists as well as hospital and CPs in the region. 
However, only currently practising members and CPs were able to participate. Eight CPs 
responded positively to the invitation and all eight respondents were contacted and 
subsequently interviewed.  
Another eight CPs who were considered to be rich sources of information were purposively 
selected for this research, and seven of the eight pharmacists agreed to be interviewed. This 




5.3 Participant Demographics 
Participant details were recorded showing the variation in the CPs interviewed (see Table 5.1). There 
was representation from all age groups, with the youngest at 25 years and the oldest over 65 years. 
As is typical of the pharmacy industry there were more females than males, with the ratio here of 
females to male being 9:6. There were twice as many pharmacy owners as pharmacist employees 
interviewed and thirteen participants worked in suburban or main street community pharmacies 
whereas two shared premises with GPs.  
Table 5.1: Participant Demographics (n=15) 
Age group Characteristic Total no. 
Age range in years 25-34 years 3 
  35-44 years 3 
  45-54 years 4 
  55-64 years 4 
  65 years plus 1 
   
Gender Female 9 
  Male 6 
   
Ethnicity European 13 
 Maori and Pacific Peoples 0 
  Asian 1 
  
MELAA  
(Middle Eastern/Latin American /African) 1 
   
Pharmacy owner or 
employee Pharmacy owner 10 
  Employee 5 
   
Extra education in 
mental health Yes 11 
  No 4 
   
Pharmacy location North Island 12 







The map of New Zealand (Figure 5.1) shows the general location of the CP participants and 
their spread over the country, i.e. six areas in New Zealand, shown by the arrows. 
 




5.4 Results from Participant Interviews: community pharmacists’ services provided 
Before specifically discussing their role in primary mental health care, CPs talked about the 
many services they provided as part of their everyday responsibilities for their patients. 
These included pharmacy services in both the dispensary and the pharmacy ‘front of shop’ 
itself. They were classified as dispensing related services, administrative services and patient 
care, which included both mental health and physical health issues. 
5.4.1 CPs’ perceptions of their role in primary mental health care: four major themes 
The services provided by the CPs revealed a large range and variability and demonstrated 
CPs’ beliefs of their role in primary mental health care. This was found to be one of four 
major themes that were identified from the participant interviews. The second theme was 
the CPs perception of the patient, the third theme was funding and education and the final 
theme was the unique context of pharmacy. These four themes are shown in Figure 5.2, 
which also shows the subthemes which were developed within each of these areas. 
 
Figure 5.2: The four major themes from CP interviews.  
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Each theme is described below in more detail, together with illustrative quotes and 
subthemes. 
5.4.2 Theme 1: Community pharmacists’ beliefs about their role 
When CPs described their work with primary mental health, three areas were identified from the 
data about the pharmacists’ role.  
5.4.2.1. Passive or active role about mental health medicines advice 
The participants showed varying levels of engagement with the patient, from extensive 
conversations in a private consulting room, to dispensing only with no further patient 
interaction as the prescription is handed to the patient by another staff member. The 
following two quotes show extensive counselling with two CPs who have included 
motivational interviewing (MI) techniques with their patients. 
People know that when they have a new medication, we’re going to 
come out with an information sheet and we’re going to go and have a sit 
in the room and people expect that. Yes, I’ve just done some motivational 
interviewing… being able to engage people and explain things in a 
realistic way… improving patient: pharmacists’ kind of dialogue. CP15 
We did a course on motivational interviewing, that was planned for nurses. Often, 
we’re used to telling people things so now we’re asking them and saying you know 
what would you need to actually do to change this and why would you want to do the 
change, what are the things you need and what are the hurdles and what can we do 
to help. CP12 
This is in contrast to the following quotes showing limited interaction. 
Some of my colleagues never give out prescriptions. They check them and they get 
someone else to give them out, they basically never go out the front. CP5  
I’m in a busy pharmacy, it’s probably handed out by somebody else. CP4 
If they are continuing medicines you just take it out… it’s just transactional… there’s 
not a lot of counselling. CP1  




People come in and tell me how they’re going with their medicine when they pick up 
their antidepressant repeats because I usually ask.CP3  
We get to see the person after they’ve had their fifteen minutes with their doctor, … 
and coming to us, we’ve got the potential to have a chat with them in a more relaxed 
way. CP8  
On a more restricted level there is engagement between CP and patient, but when initiated 
by the patient. 
I would talk to them about their condition probably only if they initiated it. CP9  
5.4.2.2 Levels of engagement with primary mental health conditions 
A minority of participants made a concerted effort to engage with patients with mental 
health issues at a broader, more personalised patient centred level. For example: 
It’s just one of those relationships, that you get out there and make a conscious effort 
to talk to them, make them feel at ease, know their name and just build a relationship 
where they feel really comfortable… once you actually start to treat them as regular 
people or you know them and look at them as a person, hey I’m going to really try 
and help them and make them feel welcome… you soon get to realise that they’re 
normal people wanting extra help. CP 12  
I think it’s about that relationship with that patient because that makes such a 
difference with mental health. You know that it really is because they don’t often feel 
like they have a lot of safe places in the community, where they can just talk or 
whatever, or people treat them like normal people. CP 7  
In contrast, a number of participants gave a variety of reasons why they did not believe it 
was up to the CP to do this or that it was not part of their role to engage with primary 
mental health conditions. 
No, I think there’s not really a mandate for pharmacist involvement… If they’re 
already talking to their GP and maybe they’ve already got a counsellor then they 
probably don’t need to talk to us, unless they’ve got a specific question about 
medicine. I think we probably realistically are only able to be involved about their 
medication. I don’t think we can talk to them about their options and we can talk to 
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them about side effects and interactions but I don’t think we can talk about the 
condition itself. CP9  
This is describing the pharmacists’ role as medication-based only. Counselling in mental 
health conditions is not seen as the CPs’ role, but only giving advice about the medication. 
This is also shown in the following quote: 
It’s more specialised, mental health, I think I’d have to be especially careful for giving 
advice relating to that because it’s not, I think stick to your knitting kind of thing. 
Medicines and side effects are as much as you can do, and then say perhaps ‘that 
needs mentioning to your GP or nurse or your specialist’. CP13 
This participant is suggesting that things associated with mental health conditions should be 
directed towards another different health professional, but not the CP. The CPs’ role is with 
the medication and side effects and that it stops there.  
Some CPs found mental health issues too discomforting or too difficult and confronting to 
deal with as opposed to physical health issues. 
I think it’s easy to start the conversation about diabetes or heart but it’s very difficult 
to start a conversation about how people feel… and occasionally you’re also scared of 
what’s going to come back at you. CP1  
Mental health is different to counselling about diabetes or cardiovascular because it’s 
their personality…I’m comfortable talking with them about medicines and side effects 
but I’m probably not always comfortable about mental health conditions. CP13  
It was also thought that sometimes the patients didn’t want to engage with any interaction 
or discussion with CPs: 
Not everyone wants to engage with the pharmacist. CP15 
And reality is that people don’t want to wait either. They’ve just spent half an hour at 
the doctor’s and it was hard enough for them to go there, they actually don’t want to 
repeat the conversation to us, they just want to get their medicines and go home. CP1 
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I’d say there’s certainly a lot of people that are probably generally well, healthy 
people that don't have a lot of interaction with the pharmacy, I would say they see us 
purely as dispensing type people. CP9 
I do engage because I’ve done extra papers and things in mental health so I feel that I 
can. A lot of people wouldn’t see a pharmacist as somebody to discuss that with and 
I’ve heard people say things like ‘that’s between me and my doctor’ they don't want a 
pharmacist involved. CP9 
However, there was variation seen and some patients were keen to follow up a discussion 
on their treatment. 
Yep so some people just don't want to discuss it and that’s fine I don’t push it, if they 
want to then I can. But you’ve got people that have already Googled everything and 
they know all about serotonin and they know all about neurotransmitters and so 
actually they’re quite capable of having a conversation about that. CP9 
 5.4.2.3 Potentially ambiguous nature of the prescription 
The potentially ambiguous nature of the prescriptions means that CPs may not fully discuss 
the treatment with the patient. Some participants described that due to the multiple 
indications of some medicines that are used for primary mental health, it was assumed it 
could be used for a number of other conditions, without this ever actually being discussed. If 
patients were not asked what the medicines had been prescribed for, the CPs would only be 
able to advise on the physical ‘how to’ of taking the drug and be unable to counsell 
effectively. This can be seen in the following two quotes where the tricyclic antidepressant 
drug amitriptyline has been the drug mentioned by both participants. 
Like if it’s amitriptyline you wouldn’t know if it is prescribed as an antidepressant, a 
lot of the time it might be for sleep or nerve pain. CP9  
If it’s the first time they’ve ever used amitriptyline or one of those tricyclic 
antidepressants then I don’t know what it’s for, it might be for shingles or it might be 
for depression you don’t know or it might be off licence for sleep. So, you never 
know… you’ve got this medicine, I’m not going to inquire what it’s for unless they 
want to start a real conversation. But I’ll just give them a tip about the practicality of 
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taking it… So, I respect their privacy but I’m trying to help them with it, taking their 
medication. CP13  
Both of these participants have not asked the patients what the medication is being used for 
and this situation has been made more difficult for CPs when there is no communication 
between the CP and the patients’ GP, and there are no shared health records. The CP does 
not know any patient history or treatment plans, which prevents them from counselling the 
patient and giving appropriate advice and guidance specific to the drug and the particular 
patient. This can be seen in the next two quotes. 
What would help us is if we knew what the doctor had talked to them about, that’s 
the biggest thing.  If we knew what the plan was if we knew what they were being 
treated for because a lot of the times I don't know if they’re being treated for anxiety 
or depression. I mean there’s a train of thought that anxious depression is the one 
and I agree with it but I want to be able to sit and talk to them about what they think 
they’re being treated for and what the doctor has told them they’re being treated for.  
I don't want to start throwing in words, phrases that somehow just disturbs 
everything and confuses things, ‘well the doctor said I have anxiety but the 
pharmacist says I have depression’. So, if we knew what the plan was, if we knew 
what the doctor had told them, if we knew that the doctors have a regular protocol 
for prescribing these then I’ll go in there, yes. CP15 
Yep well we don’t get their notes, we don’t get the doctor’s notes so we never know 
what their thinking is, or what’s behind it or anything. CP3. 
These quotes show the wide variation in how CPs think about their role in primary mental 
health care from a passive to very active role, their level of engagement and dealing with 
medication in primary mental health care. This first theme is now followed by the second 
theme of the CPs’ perceptions of the patient in mental health care. 
5.4.3 Theme 2: pharmacists’ perception of what the patient knows, thinks, wants and 
does 
CPs in their role in primary mental health services provide medication from prescriptions 
safely and legally and the procedures followed are standard and process driven. However, in 
counselling and further supportive roles there is no standard procedure or set process and 
40 
 
CPs’ activity is dependent on their own thoughts and attitudes about what the patient 
requirements are. Participants described their practice as being influenced by what they 
perceived the patient to know already, what they thought, what they wanted or what they 
perceived the patient was going to do. CPs provided services and counselling that was 
modified by what they perceived would be the outcome. Most of the CPs did make an effort 
to talk to patients newly initiated onto antidepressant treatment, and about the time delay 
before any positive effects could be felt. However, many CPs did not tell patients about side 
effects specifically, thinking that if patients were informed of these it would stop them 
taking their medication. Also, when it came time to collect repeats on their medication 
there was very little counselling involved.  
5.4.3.1 What the patient knows 
There were assumptions or beliefs from the participants about what the patients knew 
about their medication or should or should not know. As mentioned above when patients 
were newly dispensed antidepressant medication almost all of the participants made a 
conscious effort to inform the patients about certain facts regarding their medication, 
especially with antidepressants and the delayed response time before any positive effects 
begin to show. 
We usually go into the consulting room and we just have a chat…and more than 50% 
of people are surprised that it’s not going to work instantly… and I go through a 
scenario with them.CP1 
It’s something I always tell people when they are starting off, that it will take some 
time to work, I usually make sure that they know it can take a few weeks. CP9 
So I think the most important thing for us, that first starting off and checking that 
they know it’s going to take a little while to kick in, and that they understand that, 
that they just need to be a little bit patient… so that they go away not just thinking 
that it’s a magic bullet and going to work overnight. CP5 
However, many of the CPs were more hesitant in what was told to the patients about the 
side effects, believing that if patients knew too much about side effects that it would stop 
them from taking the medicine. 
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I don’t tell them a lot… often I keep it brief… I just do what I think is the essentials… so 
that they will take it and keep taking it. CP5  
Because I feel like the more side effects, I tell them the less likely they’re going to take 
it. CP3 
I don’t usually say a lot about side effects because I think people if they’re often 
anxious will hook onto that…I often try and just tell people the main side effects but it 
depends on the person. Like some people will get every side effect in the book if you 
give them a big list… the power of suggestion and that. CP14  
When the patients come in to collect their repeats there is often the perception that the 
patient has been previously told all they need to know about their medication. There is no 
counselling on follow-up visits and prescriptions are simply given out. 
If it’s a repeat of something that they have had for 3 years then I don’t necessarily go 
out. CP13 
But if it’s just a routine handing out a repeat... I wouldn’t normally ask how they are 
feeling… That would be the end of the consult. CP 9 
No. To be honest if it was a repeat prescription, or you know they’d had it before I 
probably wouldn’t talk to them about it CP5. 
This is based on the CPs’ perception of what they think the patient knows already. 
5.4.3.2 What the patient thinks 
The participants have assumptions or beliefs regarding what the patients think, such as 
these quotes regarding stigma and the CPs’ perception of what patients are thinking:  
I think it’s that whole mental health thing, that you know the way people are really 
embarrassed about depression and don’t want to kind of admit to it. CP2 
This viewpoint regarding stigma was echoed in the following two quotes:  
I think stigma is alive and well and is more in the patients mind than in ours.” CP1 
Yes, there is stigma, probably not for me but probably for them, they probably feel 
stigmatised. CP4  
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5.4.3.3 What the patient wants 
This subtheme relates to what the participants perceive the patient to want or not want. 
There is an assumption about what information the patient knows already and therefore 
what they do not want or need, i.e. perception by the CP of the need of the patient. 
It depends on the person, sometimes they have got all the information they need, 
they’ve researched it beforehand, they’ve gone to the doctor and you can tell they 
don’t want the information. CP2 
The participant has assumed that the patient will not want any further information or want 
to discuss the medication with them, but without actually asking them to find out if this is 
the case. 
We talk to them a lot about stopping and starting antidepressants… because people 
really don’t want to go on antidepressants. CP2 
People don’t want to wait…they just want to get their medicines and go home. CP1.  
However, when the CP did manage to talk to their patients the outcome was generally 
favourable.  
It is successful, they quite like it…it goes quite well… but it’s just getting there, to the 
point that you can do something. CP1  
There have been assumptions from the participants that the patient actually will take their 
medication: 
You’re hoping that they’ll start out taking it and know that their life’s going to get 
better if they do stick to it… I would imagine most of them are quite motivated.CP4  
I think a lot of our people seem to be pretty compliant on them SSRIs. A lot of them 
you don’t see as much because they’re like a 3-month stat drug. So, you’re not having 
that contact but they seem to be taking them. They tend to come and pick them up 
pretty regularly. CP10  
Without talking to the patients and discussing the medication or their condition with them, 
the assumption has been made that the medication will be taken as prescribed and that 
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there are no issues or concerns. There were no set procedures in the pharmacies to follow 
up patients’ appropriate medication usage, compliance or effectiveness of the medication.  
Community pharmacists’ actions were also modified or constrained due to a number of 
external factors, such as funding, staffing levels, time constraints, social conscience and 
education. These will all be discussed next. 
5.4.4 Theme 3: funding, staffing levels, time, social conscience and education 
Funding, necessary to a successful business, underpins all the processes within a community 
pharmacy. The funding that is available to the community pharmacy determines the 
services offered by the pharmacy, either in a direct or indirect way, especially through 
available staffing levels. Funding is also inconsistent throughout New Zealand. The national 
standard funding for all pharmacies throughout New Zealand extends to dispensing services 
only, with more specific services only being funded in specific parts of the country. Despite 
this restricted funding, CPs have provided services that they think are necessary or 
important to deliver to their patients, with or without funding. Some participants 
interviewed who were pharmacy owners showed a social conscience perspective in their 
dealings in primary mental health care by funding medicines for those who were unable to 
pay. 
5.4.4.1 Funding: national vs specific funding 
Funding on a national level is currently available for all the CPs in payment for dispensing 
prescriptions and also for long term conditions (LTC) service for appropriate patients. A 
number of other services that are also offered by CPs are not funded on a national level; 
funding is available only from specific District Health Boards (DHBs) or Primary Health 
Organisations (PHOs). Alternatively, pharmacy services can be funded by the patients 
themselves. Some of the pharmacy services available include Medicines Use Review (MUR), 
Medicines Therapy Assessment (MTA), Selective Serotonin Re-uptake Inhibitors (SSRI) 
counselling service, compliance packaging and patient medication deliveries. Of all fifteen 
CPs interviewed, only one CP received funding for the SSRI counselling service, one was 
eligible for funding for MUR or MTA, one received funding for compliance packaging and 
two received funding for delivering medication. These services were not offered by any of 
the other CPs to patients where the funding was not available on a national basis. This can 




Table 5.2: Funding of services to community pharmacies 
Nationally funded services Specific funded services 
Prescription dispensing 
(available to all CPs) 
Medicines Use Review (MUR) 
(Funded to 1 CP participant) 
Long term conditions (LTC) 
(Available to all eligible patients) 
Medicines Therapy Assessment (MTA) 
(Funded to 1 CP participant) 
 SSRI Counselling service  
(Funded to 1 CP participant) 
 Compliance packaging 
(Funded to 2 CP participants) 
 Medication deliveries 
(Funded to 2 CP participants) 
 
Some CPs could supply all of these services. Other pharmacists wanted to provide them but 
were unable to do so as no funding was available in their region in New Zealand. The 
following quotes give an example where there is funding and where funding has been 
withheld for the same pharmacy service. 
We call it SSRI Counselling… it’s a really good process so the DHB  fund it. CP12  
However, another CP in a different region in New Zealand identified that:  
I long for the PHO to come along and say we’ll give you $20 for every SSRI consult or 
something. I’ll talk about that no problems but someone’s got to give us the resources 
to be able to free up a pharmacist to spend time with people. CP15  
With the direct impact of funding on staffing levels, the time available for provision of 
primary mental health pharmacy services is restricted. 
5.4.4.2 Staffing levels and time 
One of the biggest impacts of funding is on the staffing levels in the pharmacy. Funding 
allows for the employment of sufficient staff numbers in the pharmacy and thus the 
opportunity for various pharmacy services to be available to the public. The majority of 
pharmacists talked directly or indirectly about the effect of funding on the services they 
provided. This was manifested by the way their business models played out in practice, with 
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two distinctly different management styles used, with a contrasting stance in staffing level 
and the number of pharmacists employed. 
There were just two participants at pharmacies where there was a conscious decision made 
to have more CPs employed than at other pharmacies. This ensured more CPs per number 
of prescriptions, so there was more time spent with patients, for dispensing as well as on 
patient counselling, making it safer for patients and less stressful for staff working there. 
However, this was because of a conscious decision made by the management, it was not 
because of nationwide funding from the government and it resulted in making less money 
for this pharmacy, which was not felt to be the usual accepted business practice. 
We’re very top heavy in the number of CPs we have working and I don’t believe you 
can do safe practice and deliver patient centred care unless you have that. CP10  
That’s a financial decision. I choose to deliver a level of service that I want for my 
people as opposed to making more money and that’s my decision as the owner. And 
that’s a decision I personally made and I feel good about it. CP10.  
This CP owner goes on to say: 
Any pharmacist can take as long as they need with any patient. CP10  
Another CP had this to say: 
I’m not super money driven, it’s not all about the dollars … I think some people look 
and go ‘oh my god what’s she doing running her business like that. You know she’s 
got far too many staff.’ Well actually you know, I don’t want my staff to be so 
stressed that they’re doing ridiculous amounts of scripts and that they can’t talk to 
people and they can’t do things. You know it’s kind of like a balance. CP2  
On the other hand, there were participants that described their pharmacies as being too 
busy, with insufficient staff, either dispensing or in the pharmacy, front of shop, to provide 
appropriate counselling and how stressful it was in these circumstances.  
It would be really busy. You can’t actually talk to people. It’s too busy and there was a 
rest home to look after as well as multiple packs to be made for community patients. 
You would counsell the patients but it was stressful having to leave your post and 
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leave all the scripts, to talk to people. There wasn’t a relaxed amount of time to talk 
to people really. CP4  
Also, the following two quotes show that when it is busy in the pharmacy then the 
counselling isn’t followed up with the patients. 
We probably could do more counselling, some people we certainly could… limiting 
factor is, if it is really crazy busy in the shop then we don’t. CP9  
Our business model has a certain number of pharmacists in the shop at any given 
time… but we still get stuck. At certain times of the day we are so busy that we are 
just head down getting through the load of prescriptions, check them and give it to 
them, as we have someone else waiting. CP1  
Employee pharmacists did not always follow the direction of owners or managers, but did 
things they thought were necessary for the patient: 
If I want to say something to someone, I will say it, I will always try and if they wanted 
to say something, then they could. I don’t worry about the funding because I’m an 
employee. CP13.  
The following two quotes give similar examples whereby the participants counsell even if it 
is not actually sensible from a business or commercial point of view. 
From a commercial point of view, it just doesn’t make sense, it’s time not well spent, 
20 minutes on one patient. Like if they need it, absolutely I will, but… CP3 
I had one patient that took nearly half an hour… validating the doctor… I don’t get 
paid for doing it but somebody had to do it. CP15  
However, as an employee sometimes there were funding constraints and limitations which 
could not be overcome and services could not be provided, despite wishing to do so. This 
was seen in the pharmacist employee who was the sole charge pharmacist, who wanted to 
provide a level of service but was not able to: 
It would be nice to sit down and talk to them about their medicines and their 
condition but… during peak times I just give it to one of the shop staff and out the 
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door it goes... so that’s a downside of being sole charge is I don’t have the time to talk 
to people. CP3  
Despite the lack of funding some CPs interviewed created alternatives showing a definite 
social conscience, as follows. 
5.4.4.3 Social conscience 
A majority of pharmacy owners showed high levels of social conscience by offering various 
pharmaceutical services even when there was no funding forthcoming or insufficient 
funding. Costs were sometimes covered by the CPs themselves. This can be seen in the two 
following quotes where a credit system has been set up for the patients and allows them to 
take their medication home, despite insufficient funds. 
I say ‘look if you can’t afford it, put it on the account and you pay it off’. On the whole 
they’re pretty good, but every so often we get let down. CP10  
While another participant stated:  
I say to them “Just pay it when you can or go to Income Support” or whatever. But 
you know we don’t, we wouldn’t let anyone go away without their medicine.CP8  
The following participant is cognisant of costs and the possible results for the patients in the 
area for increased costs: 
We don’t charge for fax prescriptions. We’re one of the few people in the area. Our 
mental health patients couldn’t pay it and it would be another barrier that we’re 
putting up. CP2  
5.4.4.4 Education of CPs in primary mental health care 
Most CPs interviewed were interested in upskilling and doing courses in mental health, and 
many had completed some extra study previously in mental health care. 
No, I would love to have a communication course, on how to actually talk , how to 
broach the subject, how to start the conversation as I think once we start the 
conversation it’s okay, I think most pharmacists can deal with it once we start but I 
think it’s getting everything in place to start the conversation .CP1 
I do make a point of doing continuing education. CP5 
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Obviously, that’s part of your continuing professional development and everything as 
well so you know it’s for me, I would be interested in doing more courses. CP3 
CPs also have often experienced times when their training, skills and expertise are not 
acknowledged by members of the public. 
Yes, definitely yeah there’s still a lot of people that aren’t aware that we know as 
much as we do. A lot of people think we just pack and wrap from a piece of paper.CP3 
You do get people that say well you’re just putting a label on the box… And it is 
probably pharmacies in general has not been very good at promoting it, and telling 
people what we do. Yep and we are just seen as giving out medicines. CP2 
Some people think you’re just a fish and chip retailer and it’s an easy prescription, 
why can’t it be ready in two minutes. Some people highly value what you do and then 
other people place no value on it. CP4 
People are unaware that we’re clinically trained enough. So that’s more to do with I 
guess the profession raising its profile of what we do. You look at medical professions, 
they are well respected, people know if you’re got a problem go see your doctor, they 
don’t really think of pharmacists like that. CP3. 
5.4.5 Theme 4: unique context of pharmacy 
As primary health care providers, CPs have a unique status, offering a multitude of services, 
some very private and personal, despite being in a distinctly public space, i.e. at a counter in 
a retail setting. Community pharmacy not only offers services that include dispensing of 
medication as its primary function, but also offers a broad range of other services. These can 
be medication or non-medication related, and inclusive of basic determinants of health and 
advocacy when needed. It can be the first port of call in health care before being directed to 
other health care providers. It also offers a sense of belonging in the community with many 
relationships being formed on a variety of levels. Community pharmacies hold a unique 
place within the community.  
5.4.5.1 The place of pharmacy in the community 
One participant who provides a broad range of services, often beyond just medications, 
described the place of pharmacy in the community in the following way: 
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They are comfortable with us and they come to us if they’ve got any problems quite 
often now. Sometimes some of them come because they have no power or they’ve 
got no food and they know that if they come to us, we will go to the relevant people 
that will help sort that for them. I mean we can’t have people sitting at home with no 
power or no food. CP6. 
This shows the range of help and service that they can and do provide outside of just 
medicine supply. This quote was from a pharmacy where there had been inter-generational 
relationships built up over the years and the CP and pharmacy team were very much an 
integral part of the community.  
The next two quotes show how this CP and his staff do more than just supply medication, 
but make sure that their patients have not misplaced the medication and arrived home 
safely. 
So, we got to a point with her because she didn’t have any family around where we 
are, one of the girls from work popped in on her way home and made sure she had 
her pills. CP8 
You know we’ve got an old guy comes in is a bit unsteady I’ll send one of the girls 
home just to watch him to make sure he gets there or take him home. CP8 
Yet another CP stepped in for her patient when the patient fell out with her GP and could 
not access a new GP. This CP was an advocate for her patient, helping her when she was not 
able to do so herself. 
I rang and I said this is the case, we need another doctor for her, can you help her. 
And they said yes, she’s better off to see this doctor because she’s quite good with 
mental health…. And she (the patient) didn’t have the ability to find another doctor 
and if I hadn’t done it she wouldn’t have gone to see anybody. CP7 
Pharmacies are also often the first point of contact when there are health emergencies or 
uncertainties, for patients to find out what they should do next or where they should go. 
This can be seen with the following participant: 
We do the triage. Basically, I call us the emergency department for primary care. So, 
our triage is ‘can we treat you or do we need to refer you on to your GP?’, and in 
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some cases ‘do we need to refer you on to somewhere else… or we can point you in 
the right direction? CP10. 
This pharmacist goes on to explain the relationships and being part of the community:  
We’re part of the community. Often people will see the doctor once a month, or once 
every three months, but we are probably seeing them a bit more regularly than that 
because we see them in between when they come in and buy things. In my early days 
you enrolled with a GP, now you enrol with a practice. So that means the 
relationships not there at the doctor’s level and that’s where I think pharmacists are 
more important because actually, we’ve perhaps got a little bit more continuity now. 
CP10  
5.4.5.2 Physical environment 
The physical environment that is the community pharmacy for all the participants varied 
from very small stand-alone pharmacies to much larger pharmacies located within suburban 
malls. The one constant factor in all the pharmacies was the presence of a shop counter 
where the transactions take place between the CPs and their patients. In most pharmacies 
there has been the addition of a consulting room, which gives the patient privacy for a 
consultation which would otherwise take place in the open space, within the pharmacy. 
One pharmacist explained the situation at the counter: 
You’ve got the counter there and definitely I try and come out round, but you’re not 
going to ask ‘how are you doing today?’ over a counter. CP1 
This was also reflected by the following CP: 
At the front counter it’s all go, people drop off their scripts, people are buying stuff, 
it’s just too hectic to consult with anyone. CP3  
However, this was not always seen as a hindrance to service or as a difficulty and some 
pharmacy customers became accustomed to this service provided at a counter as seen by 
another participant: 
Most people are pretty open and they’re used to having to stand at the counter and 




However, the counters are very public spaces and other participants used different parts of 
the counter to advantage, in different ways. This can be seen in the following example to 
show a patient their own information in the pharmacy database:  
We’ve got several screens and we’re got one right at the end of the counter, so I just 
say come and stand with me, it’s one of the curvy benches on the end… we can just 
tip this screen a little bit and then we can have a look and then we’ll just work 
together, because it’s their information, it’s their file and I can show it to them. CP13  
Other pharmacists though had abandoned the counter in preference to using the consulting 
room. These came in a number of guises, with offices, storerooms, unpacking rooms and 
tearooms being converted when necessary. 
You’ve got to make sure that they’re comfortable so that’s when I’ll say should we go 
have a chat in the office CP11  
Consulting rooms did provide a space for privacy in a busy community pharmacy, but when 
this was not available several of the CPs resorted to a quiet area in the pharmacy or even 
continued the consultation outside the pharmacy: 
If it’s a private thing and people say I’d like to talk to you, I can go into a corner of the 
shop… and just talk quietly. CP14 
Several CPs went outside the premises to continue speaking with their patients in private, as 
seen with the next two participants: 
I’ve taken people outside, sometimes it’s more private outside the front door than it is 
in the pharmacy. CP13  
We have got a counselling room but it’s quite small, so often we end up talking out in 
the carpark. CP10  
So, there were many ways that the pharmacy environment lent itself to being used for 





Considerable relationships can be formed within community pharmacies and there can 
sometimes be empathy and understanding demonstrated, where people with primary 
mental health issues are treated no differently to any other people. This can be seen below: 
You suddenly realise that it’s not just one or two people, it’s just heaps and heaps of 
people and I think we can all identify with it to some degree. It’s a widespread thing 
and real tough thing for that person and you’ve got to make allowances for that.CP8  
Also, another important relationship can be seen in the following: 
I had this woman who moved out of town, but she came back in to thank me because 
we knew her name and you don’t realise how those little things like just knowing a 
person’s name makes such a difference to them.” … “And there’s been other cases, 
but you see, two years down the track they’re not like that at all and so it’s really nice 
remembering what they were like and then going we haven’t seen that for so long 
now. CP7 
This is what one participant said about the relationship with their patients: 
You’re their pharmacist. You’ve built a relationship, you know that they trust you, you 
know that they will ask for help and that’s nice. We have relationships and from those 
relationships come trust. CP5  
This trusting relationship is seen in the next quote where the CPs are trusted in some 
situations more than the GP. 
I often think people are more willing to talk to us than they are to even GPs at times 
you know because you get to know them over a long period of time and they will 
often ask us things that are worrying them. CP8  
The relationships formed within the pharmacy exists between the CP and carers, spouses 
and family of the patient.  
Carers and spouses, they’re key and we listen to them and we often get them ringing 
in saying I’m concerned or whatever. We take them seriously and we give them a 
mechanism. A path to go down to try and get things resolved. CP8  
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A further relationship which is important for all CPs is the relationship with the GPs and staff 
at the local medical centre or GP practice. The majority of CPs described relationships as 
being good, although there were still some problems and frustrations with communicating 
with the GPs with ‘gatekeeper’ receptionists. 
There are more barriers in place to actually getting through to doctors. CP 2 
In just one DHB, the GPs and CPs were able to communicate by a computer messaging 
system, which provided an even closer means of communication which was direct, quick 
and very effective: 
You can get straight to the doctor if they’ve logged onto their computer. CP14 
In general, there was a good working relationship between the CPs and the staff at the 
pharmacy with the GPs and the medical centre. 
We’ve got a reasonably good relationship, the doctors know that certainly in our 
pharmacy we call them a lot with queries, with requests, we’re very proactive. CP15 
We’ve got a good relationship with all the doctors. CP6  
The following describes an especially close working relationship between this CP with their 
local GP: 
So, it’s a really good relationship and it’s honestly like the best kind of win-win 
situation that I see because you know I’m supporting them and they’re supporting 
me. CP11. 
5.5 Results Summary 
The results of fifteen face-to-face interviews with CPs throughout New Zealand have been 
described in this chapter, with the use of direct quotes to illustrate the points made. 
Thoughts on primary mental health care in community pharmacy varied widely but could be 
organised into four main themes. One major theme showed the range of beliefs CPs had 
regarding their role in primary mental health care. They all displayed a positive attitude 
towards primary mental health and their role, but there were varying degrees of 
engagement with patients with primary mental health issues, in particular an active or 
passive role. The CPs’ actions are influenced by their perceptions of what they think the 
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patient knows, thinks, wants and does. There were a number of situations where the 
participants acted on the premise of what they thought the patient wanted, but patients 
were not always given the opportunity to actually express what they wanted. Funding is an 
important contributor to the services that are offered, as funding affects community 
pharmacy staffing levels and therefore the capacity and time to provide services. Primary 
mental health services provision is also similarly influenced with alternative funding sources 
which are not uniformly available for all pharmacists, but only for some pharmacists in some 
areas. Some pharmacy owners also provided personal funding. The unique context of 
pharmacy has been demonstrated, showing the provision of personal health services in a 
public place, a retail centre. Despite privacy being a possible hindrance to the provision of 
pharmacy services, the CPs showed insight to overcome this for the sake of their patients 





This chapter discusses the results presented in the previous chapter. To address the aim of 
this study it discusses the CPs’ overall perceptions of their role in primary mental health 
care, the services they provide for primary mental health care and factors that affect this. It 
begins with an overview of the key findings. Each key finding is then discussed more fully in 
association with relevant literature and key policy documents. The chapter concludes with 
an overview of the strengths and limitations of this research. 
6.1 Overview of Key Findings 
There were three key findings from the results of this qualitative study. The first key finding 
is that all the community pharmacists (CPs) believe that they have an important role to play 
in primary mental health care, although the roles and services provided were of a wide 
range and large variation, meaning there was variable potential to improve patient 
outcome. These services formed a continuum of mental health services, with the span 
ranging from the dispensing of prescriptions through offering a range of extended pharmacy 
services, to providing broader patient centred primary mental health care. CPs are educated 
to be the medication expert, however this study shows their services extended beyond the 
technicalities of medication side effects and adverse drug reactions and included providing 
support, facilitating for, and being an advocate for the patient in significant ways. They often 
acted as intermediaries between the patients and other health care professionals to bridge 
gaps in care, providing continuity of primary mental health care, along with other health 
care needs.  
The second key finding was that all CPs endorsed the importance of the long-term 
relationships they hold with patients in delivering effective care to this patient group. 
Community pharmacies provided places of safety, where trusted and supportive 
relationships between CPs and patients with mental health issues could be developed and 
grown, sometimes intergenerationally.  
The third key finding involved factors which affected CP service provision to patients with 
primary mental health issues. These factors included limitations of time and funding, privacy 
and confidentiality and stigma related to mental health. It was also found that the 
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perceptions of the CP influenced the services that they provided. These key findings will be 
discussed in turn. 
6.1.1 Key finding 1: Community pharmacists’ role & services: an important role to play 
From this research, all the CPs felt they had an important role to play in primary mental 
health care, although the roles varied and some CPs played a larger role than others. The 
CPs’ traditional medicine dispensing role has expanded to now include extended clinical 
pharmacy services not only involving the patient’s medication, but beyond this to provide 
broader patient centred care. This can be seen diagrammatically as a continuum of care 
with the primary mental health services available from CPs, shown in figure 6.1. 
 
Figure 6.1: A continuum of primary mental health services. (LTC, Long term conditions; 
MUR, Medicines Use Review; MTA, Medicines Therapy Assessment.) 
 
In this study the range of services starts with CPs offering the dispensing of prescriptions. At 
this point on the continuum, the CPs also acted as patient facilitators when necessary, 
liaising with GPs and the primary health care team to provide prescriptions that were 
appropriate, safe and legal, as this is not always the case. These were generally 
administrative issues as opposed to being clinically based. This ensured prescriptions could 
be safely dispensed and was generally reliant on the CP acting on behalf of the patient to 
make contact with the prescriber. 
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Moving along the continuum, CPs are able to offer patient counselling, which is educating 
and giving advice to their patients on drug side effects, adverse drug reactions and various 
specific services, such as the Medicines Use Review (MUR) service. At the end of the 
continuum there is extensive engagement between the CPs and patients, showing broader 
patient centred primary mental health care. The CP at this stage shows involvement with 
other health care professionals in the multidisciplinary primary health care team in the care 
of the patient, these being the GP, practice nurse, and the community mental health team. 
This extended communication helps to ensure the patients are getting appropriate 
medication as intended, in mental health care as well as all other aspects of the patients’ 
health care. There is feedback to the prescriber and other health care professionals, if and 
when necessary. In this way CPs have provided continuity of primary mental health care 
with the continuous ongoing supply of mental health medicine. 
At this end of the continuum of services, the focus has changed to be centred on the 
patient. Motivational interviewing, seen with a small number of CPs in this study, assists 
patients in their treatment process. Some CPs in this study acted as patient advocates, and 
provided support for the patient by showing empathy and understanding, and gave patients 
a place where they could feel safe and secure. This role of the CP has been mentioned in the 
literature by Australian researchers Mey et al in 2013, in a qualitative survey with focus 
groups and semi-structured interviews, describing the safe places that CPs can provide.28 At 
the far end of the continuum a small number of CPs in this study provided essential care to 
the patient, beyond general health and well-being. In one example the CP set up and 
ensured the patient had access to GP services, when circumstances caused the patient to be 
without medical support. In another instance the CP has helped when there have been 
problems with even the most basic of essentials such as food and power, when the patient 
was unable to. Services of this nature are not well documented in current published 
literature in New Zealand or internationally. 
The results from this research found CPs predominantly focused on advising patients when 
they were newly initiated on their treatment for mental illness and patients were given 
information reasonably routinely regarding the delayed response to antidepressants. This 
focus by CPs on initiation of treatment has also been documented in the literature.36,75 
However, this strong focus at the initiation of medication did not generally continue past 
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the collection of the first repeat prescription. The follow-up monitoring of treatment 
efficacy or medication adherence and compliance of mental health medication did not occur 
as a regular activity for mental health patients. This lack of ongoing support has also been 
described in a UK study85 and several Canadian studies.75,103 This indicates that the majority 
of CPs see the importance of their role as being when patients are newly diagnosed and 
receiving their medication for mental health care for the first time, but not in the 
monitoring of efficacy or follow-up advice for the continuation of their treatment.  
6.1.2 Key finding 2: relationship with patients  
In this study a consistently important factor was the trusting and supportive relationship 
most of the CPs formed with their patients. It appeared that close relationships built up 
between the participants in this study and their patients resulted in positive engagement 
between them, allowing open communication and the sharing of information. The 
participants knew their patients well, there was establishment of rapport and CPs were 
sometimes patient advocates in the health care system. CPs demonstrated empathy for and 
understanding of patients and provided greatly needed reassurance regarding their 
medication and health care needs in both mental and physical health care if necessary.  
The depth and quality of these relationships has also been described in literature from 
Canadian, US and New Zealand sources.52,56,60,63 In this study, relationships were described 
by some as long term and families were known intergenerationally. This increased the level 
of trust and support and has strengthened the CP and patient bonds.  
6.1.3 Key finding 3: factors affecting the CPs’ provision of services 
There were some overall factors identified which affected the CPs’ provision of services and 
acted as either barriers or facilitators, depending on the circumstances. These include time, 
funding, privacy and confidentiality, stigma and also CP perceptions of those with primary 
mental health conditions.  
6.1.3.1 Time and funding  
This study identified that both insufficient time and funding negatively impacted on the 
provision of services by CPs for their patients and that these factors are intrinsically related. 
These factors have both been noted as barriers in many previous studies.35,63,75 The lack of 
time available for provision of services can be linked to lack of staff, which can in turn be 
due to the absence of funding. However, in this current study it was seen that these barriers 
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were overcome in several situations by the pharmacy owners hiring more CPs, who were 
subsequently able to offer more services to their patients and eliminate the barrier of lack 
of time. This was not achieved through government funding but by the owner self-funding, 
which resulted in a lower profit margin from their business. However, this had been done 
knowingly for the good of the patients. Several CPs who were not pharmacy owners 
admitted to offering services knowing they were not economical for the business, but doing 
so for the benefit of the patient. Thus, there were things done that resulted in increased 
service provision, but these were at the expense of the pharmacy owner. Crump et al60 
similarly noted this in a 2011 New Zealand qualitative study, that the CPs provided services 
to those needing mental health treatment, despite the lack of funding, acknowledging the 
need of the patient. However, the absence of regular funding on a national level means 
inconsistent nationwide service provision and also compromises the viability of the 
pharmacy as a profitable ongoing business.  
A second funding barrier is the funding of pharmacy services from the District Health Boards 
(DHBs) or Primary Health Organisations (PHOs). These pharmacy services are not 
consistently funded across the country, but dependent upon the individual funding 
organisations. This sets up an inequitably accessible system and many CPs do not provide 
these services, but they would be keen to do so if funding was available. Within this range of 
services is SSRI counselling, compliance packaging and medication deliveries, MUR and MTA 
services.  
6.1.3.2 Privacy and confidentiality 
The lack of privacy and confidentiality was mentioned by all CPs, with the pharmacy counter 
being recognised as a particular deterrent to patient counselling in prior research.103,104 
While the counter provided a physical barrier, and a focal point of the pharmacy, its general 
busyness can inhibit patients from asking to speak to the pharmacist and then from 
speaking freely. Despite this, the majority of participants in this study felt that privacy and 
confidentiality could be maintained, by moving away to a consulting room or a quieter 
counter, or any other quiet space available in or outside the pharmacy, such as outside the 
front of the pharmacy or in the carpark. Although privacy and confidentiality has been 
important for CPs, research into alternative locations for patient counselling has not been 
identified in other recent studies. 
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6.1.3.3 Stigma and education as barriers 
Despite the positive attitudes of all the CPs towards primary mental health care, a small 
number of participants in this study felt that they could not discuss primary mental health 
issues with patients. This was due to the difficulties and uncertainties they perceived were 
associated with mental health, which are not encountered with physical health conditions, 
such as heart disease or diabetes. This is reinforced in the literature, which also shows that 
services provided to patients with mental illness are fewer than services provided to those 
with physical illnesses.68-70 Barriers to provision of care may be associated with stigma and 
CPs’ discomfort dealing with patients with mental illness,65,105 with stigma of health 
professionals towards those with mental illness well examined in the literature.64,106,107 A 
number of researchers believe that stigma is due to lack of education and understanding 
and when attention is paid to these two areas, then stigma can be greatly lessened.72,108 
Generally, the CPs in this study felt that they were adequately trained in primary mental 
health care but some stated that they would like to participate in more training, especially 
in communication and taking part in primary mental health workshops. It was found that 
the two CPs who had the most understanding and empathy towards those patients with 
mental illness had no extra education or training. These CPs however, did have greater 
involvement with other health care professionals in their locality. This greater involvement 
with other health professionals appears to be a facilitator for pharmacy services, which can 
be seen in collaborative studies between CPs and GPs and the interprofessional team in 
mental health83 and in general health care.109 
6.1.3.4 Community pharmacists’ perceptions as a barrier 
The lack of primary mental health service provision, however, may be due to perceptions 
that some of the CPs held and which acted as barriers to service. Some CPs in this study 
described not providing information or interacting with patients. This was due to their 
perception of what the patients knew already, or thought, or wanted or what the patient 
would be likely to do. Some participants felt that patients already knew enough about their 
medicines and/or condition, or had acquired information from the GP or the internet, or 
both. Some of the CPs did not provide information because they believed that patients 
would make a conscious decision to disregard professional advice and avoid taking their 
medication if they were given more information. There was also the perception that the 
patient did not want interaction or discussion, or did not want to engage with them. 
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From all the literature searches only two sources mentioned CPs perceptions, one being 
from the UK in 2002 51 and the other from Canada in 2001.110 These sources reported that 
CPs perceived patients were reluctant to talk to them about depression and lacked interest 
in discussing their treatment. Despite this, the literature has shown that when asked, 
patients requiring mental health care want more information and they feel that the 
information provided to them has at times been insufficient.41,56,85,111,112 
Two of the CPs believed it was not their role to discuss the primary mental health condition, 
just the drugs themselves, and that it was pushing beyond the boundaries of what CPs 
should do, to discuss anything further than how to take the medication. This is further 
reinforced by the ambiguity of some drugs which are used for multiple conditions. As CPs do 
not have direct access to patient medical records, patient history or their treatment plans, 
they are unable to give further counselling or advice for the patient. As more health 
information is shared via electronic records and CPs become integrated into primary health 
care teams, which is the direction of the NZ Health Strategy11 and The Pharmacy Action 
Plan,16  this will no longer be a barrier. Shared electronic records will also facilitate the 
provision of individualised primary mental health care services. 
6.4 Discussion Summary 
This research demonstrated an overall positive attitude, interest and willingness of the CPs 
to provide primary mental health care, with an extensive range of services offered. Some 
CPs demonstrated proactive roles in both pharmaceutical and psychosocial care, while 
others were more limited in the services they provided. Published literature to date in this 
area from the US,65 UK,66 and Europe69,70 similarly demonstrated CPs having an overall 
positive attitude, interest and willingness to provide services for primary mental health care. 
There were many of the same barriers to the provision of care, which includes time and 
funding, although this research found the perception of the CPs could be an added factor to 
limiting service provision. 
6.5 Strengths and Limitations 
This qualitative study resulted in new and different data with a greater depth of 
understanding of CPs’ experiences in primary mental health care. There were fifteen 
interviews which were all carried out face to face. Being interviewed in person helped to 
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foster a relationship between the interviewer and interviewee, and enhanced the depth of 
information obtained. Combined with the flexibility of questioning, rich information could 
be obtained from the participants with in-depth information from individual cases capturing 
responses to local conditions. The researcher was able to change focus depending on the 
direction the interviews were taking and an iterative process with the interview schedule 
was able to be used. The participants were able to interpret all questions in their own way 
and were not hindered by set structures. This was respectful of the participants involved. 
Limitations of this research was characteristic of qualitative research with data gathering 
and data analysis being particularly time consuming, especially in comparison to 
quantitative analysis. Despite a number of different ethnicities among the participants, 
there were no Māori or Pacific Island group respondents, which reflects on the low numbers 






This chapter discusses the conclusions that have been reached from this qualitative study of 
fifteen community pharmacists (CPs) and their perceptions of their role in primary mental 
health care. 
The CPs in this study all displayed a positive attitude towards their role in primary mental 
health care, although there were different levels and variation of service delivery and both 
active and passive engagement with patients was identified. They provided a range of 
services which extended beyond supply of pharmaceuticals to include clinical services (such 
as the provision of drug information, advice on adverse drug reactions, side effects and 
medication management) and broader patient centred care. This extra care included 
navigating the health care system and ensuring appropriate continued drug treatment in 
their primary mental health care and other physical health care. In doing so, many formed 
strong, trusting relationships with their patients and acted as advocates for these patients in 
the health care system. 
Despite this, there were a number of factors which impacted the provision of primary 
mental health services that the CPs in this research would have liked to provide. These 
factors need to be overcome for CPs to be able to contribute more fully. They are specific to 
the organisation of community pharmacy including funding, staffing levels and the 
availability of time. Privacy issues and lack of education were barriers that could be 
overcome to facilitate their contribution to patient care, but stigma and some CPs’ 
perception of patient needs are barriers to further service provision and care. These are 
harder to address. Continued work in this area, likely through ongoing education, would 








There are a number of recommendations resulting from this study which have been divided 
into three groups. The first group is recommendations for community pharmacists (CPs), the 
second group is for policy makers, health care leaders, decision makers and researchers and 
the third group is for pharmacy professional bodies. 
8.1 Recommendations for Community Pharmacists 
1. CPs to undertake patient counselling and provision of services to patients, not just at 
the initiation but for the duration of the patients’ primary mental health treatment. 
Over the course of treatment CPs could monitor patient responses to their 
medication treatment, side effects and drug adherence or compliance and more 
generally check on well-being and give more information about lifestyle and or 
community resources, as necessary. 
2. CPs to opportunistically undertake depression screening as part of mental health 
care service.  
8.2 Recommendations for Policy Makers, Health Care Leaders, Decision Makers and 
Researchers  
1. Policy makers, health care leaders and decision makers should implement 
routine sharing of key aspects of the patient’s electronic health record between 
relevant health care providers. Key information would include patient history, 
diagnoses, medicines, health and social care professionals involved and other 
treatment plans. 
2. Appropriate and consistent funding for pharmacy services such as MUR, MTA 
and the SSRI counselling service, to be available to all CPs throughout the 
country, thus removing any inequities of access. 
3. Promotion of the CP’s role in primary mental health care (as well as their other 
roles), so the general public have an increased awareness and understanding of 
the capabilities of the CP. This would allow the public to be able to make greater 
use of the CP’s skills and expertise. 
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4. Research to be undertaken on patients’ experiences in community pharmacy, in 
relation to their primary mental health care. There is a scarcity of New Zealand 
research on patients’ requirements in relation to primary mental health care and 
their perspective of what is provided from CPs in this area. 
8.3 Recommendations for Pharmacy Professional Bodies 
1. Promotion of the CP’s role in primary mental health care (as well as their other 
roles), so the general public have an increased awareness and understanding of the 
capabilities of the CP. This would allow the public to be able to make greater use of 
the CP’s skills and expertise. 
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Appendix A Table of Pharmacy Services 
 
TABLE OF PHARMACY SERVICES*  




Blood Pressure Measuring 
Bone Density Scanning 
Clozapine Dispensing 
Compliance packaging (blister packs) 
Dispensing Prescriptions  
DHB2 funding (Varies across DHBs) Medicines Disposal  
Education/Advice on health concerns 
Education/Advice on OTC3 medicines  
Education/Advice on prescription medicines 
Home delivery service 
Long Term Conditions  
Medicine Therapy Assessment 
Medicines Use Reviews 
Methadone Program 
Needle Exchange 
Prescription depot service (rural areas) 
Smoking Cessation  
Special Foods Services  









CPAMS1 Community pharmacy anticoagulation monitoring service                
DHBs2:District Health Boards 
OTC3 Over the counter                 




Appendix B Literature Review Search Methodology 




Results Generated From: 
Ovid MEDLINE(R)  
 
Set   Search                                                         
-------------------------------------------------------------------------- 
001   Pharmacists/                                                      
002   Education, Pharmacy/ or Education, Pharmacy, Continuing/          
003   Professional Role/                                                
004   scope of pract*.mp. [mp=title, abstract, original title, name      





      word, keyword heading word, organism supplementary concept 
       word, protocol supplementary concept word, rare disease  
      supplementary concept word, unique identifier, synonyms]      
005   Safety/ or Safety Management/                                     
006   community mental health services/ or counseling/                  
007   Antidepressive Agents/                                            
008   Health Promotion/                                                
009   Professional-Patient Relations/                                   
010   social stigma/                                                    
011   qualitative research/                                            
012   (qualitative or experience* or view* or attitude*).mp. [mp=title    
       abstract, original title, name of substance word, subject 
      heading word, floating sub-heading word, keyword heading 
       word, organism supplementary concept word, protocol supplementary 
     concept word, rare disease supplementary concept word, 
     unique identifier, synonyms]                              
013   11 or 12                                                        
014   2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 13               
015   Community Pharmacy Services/                                      
016   counseling/                                                       
017   14 or 16                                                        
018   1 or 2 or 3 or 4 or 5 or 7 or 8 or 9 or 10 or 13 or 16          
019   1 or 15                                                           
020   18 and 19                                                         
021   mental disorders/ or anxiety disorders/ or panic disorder/ or     
       phobic disorders                           
022   Depression/                                                      
023   21 or 22                                                        
024   Community Mental Health Services/                                 
025   23 or 24                                                        
026   18 and 19 and 25                                                    
027   qualitative research/                                            
028   (Qualitative or experience* or motivate* or ethnograph* or    
      phenomenon* or attitude* or view* or knowledge).mp. [mp=title, 
       abstract, original title, name of substance word, subject  
      heading word, floating sub-heading word, keyword heading word 
      , organism supplementary concept word, protocol supplementary 
       concept word, rare disease supplementary concept word, unique 
       identifier, synonyms]                                    
029   (belief* or perception* or interview* or "focus group" or     
     “focus groups").mp. [mp=title, abstract, original title, name 
      of substance word, subject heading word, floating sub-heading 
      word, keyword heading word, organism supplementary concept 
       word, protocol supplementary concept word, rare disease  
     supplementary concept word, unique identifier, synonyms]        
030   28 or 29                                                        
031   27 or 30                                                        
032   1 or 15                                                           
033   6 or 7 or 21 or 22 or 24                                        
034   32 and 33                                                          
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035   (Qualitative or experience* or motivate* or ethnography* or     
      phenomenon* or attitude* or view* or knowledge).m_title.        
036 (belief* or perception* or interview* or "focus group" or     
 “focus groups").m_title.                                        
037   35 or 36                                                        
038   1 or 15                                                           
039   37 and 38                                                          
040   33 and 39                                                           
041   7 or 21 or 22                                                   
042   27 or 35                                                        
043   36 or 42                                                        
044   42 and 43                                                       
045   32 and 44                                                         
046   *Antidepressive Agents/ or (*mental disorders/ or *anxiety      
      disorders/ or *Depression/                                    
047   19 and 46                                                           
048   27 or 37                                                        
049   19 and 48                                                         
050   23 and 49                                                           
051   "Attitude of Health Personnel"/                                 
052   46 and 51                                                         
053   19 and 52                                                           
054   32 and 37 and 46                                                    
055   53 or 54                                                            









Set   Search                                                       
-------------------------------------------------------------------------- 
001   Pharmacists/                                                      
002   Community Pharmacy Services/                                     
003   1 or 2                                                            
004   mental disorders/ or anxiety disorders/ or panic disorder/ or    
       phobic disorders/  
005   Depression/                                                      
006   4 or 5                                                           
007   (experience* or motivate* or ethnography* or grounded theory     
      or phenomenon* qualitative or attitude* or view* or knowledge 
       or belief* or perception*or interview*).mp. [mp=title, abstract, original title, name   
of substance word, subject heading word, floating sub-heading word, keyword 
heading word, organism supplementary concept word, protocol supplementary 
concept word, rare disease supplementary concept word, unique identifier, 
synonyms]                                        
008   3 and 6 and 7                                                       
009   limit 8 to english language                                         
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010   "role*".ti,ab.                                                 
011   3 and 6 and 10                                                      
012   limit 11 to english language                                        
013   9 or 12                                                             
014   limit 13 to updaterange 
                                                              
 
 





Appendix C Interview Schedule 
To explore community pharmacists’ perceptions of their role in primary mental health 
care 
Mental Health – general: This study is researching primary mental health conditions 
(PMHC). Generally, these are thought to include mild to moderate mental health conditions 
where people can still continue to function, that affect people like you and I, i.e. depression 
and anxiety. 
• Think of the last mental health prescription in your pharmacy and tell me about that 
interaction (e.g. the last antidepressant prescription that you did). How often does 
that happen?  Maybe once or twice a day or once or twice weekly? This is to give 
some idea of the number of mental health customers/patients 
• So how many mental health patients/customers do you think you have coming to 
this pharmacy?  
Mental Health – specific 
There are probably many occasions that you may want to or could do particular things but 
are unable to, but in general: 
• What do you see as the role of pharmacists in relation to mental health patients? Do 
you think you have a role or does anybody else in the pharmacy/dispensary? Would 
you like to have a greater role? 
• Do you feel prepared/adequately supported for this role?  
• In general, how comfortable do you feel talking to these patients about their mental 
health conditions? (tease out anxiety then depression) 
• What would make you think someone in the pharmacy may have depression? 
• What would make you think someone in the pharmacy may have anxiety? 
• What role might you play in the diagnosis of either/both anxiety or depression? 
• What do you know of the typical treatments for anxiety and depression (talking 
therapy or psychotherapies/counselling and their local availability as well as 





Mental Health – medicines 
In general, when a patient has their first prescription for antidepressant or anti-anxiety 
treatment… 
o Do you have a routine or procedure with your mental health patients that 
you follow?  
o How do you assess how much information the patient needs, or what they 
know already? 
o How do you deal with the issues of drug interactions and their adverse 
effects? 
o Do you talk about adherence and compliance? (Probe: are there particular 
methods/techniques that you use to discuss these?) 
• In general, how do you manage patients with their subsequent prescriptions? What 
do you say to people when they pick up their repeats? 
• How often do you sell medicines for mental health? (probe: OTC sales of sedatives 
and natural products/complementary/herbal remedies St John’s Wort) 
When your staff have OTC sales, do they ever/generally/never ask you to assist and 
counsell patients? 
• In general, how comfortable do you feel talking to these patients about their 
medicines? 
• Where do you talk to your customers when you need to counsell them? (Probe: do 
you feel this is a good environment to talk to them in?) 
Barriers to care 
• What might be barriers to giving care for mental health in the pharmacy? 
(Sensitivity of depression, knowledge, time, space, privacy, payment for services, 
work flow/processes in place or not?) 
• Are there barriers that you can think of that I haven’t mentioned? 
• How often do you counsell or advise your patients about their medications or 
health generally? (Probe: is this the same for people with mental health issues?) 
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• What is stopping you from doing what you would like to for mental health 
patients? Does this happen?  
 
Collaborative care 
1. In general, how do you usually interact with local/other health professionals in 
primary care? And secondary care? (Probe: general practice GP, practice nurse, 
reception, district nurses, hospital clinic, physiotherapist.)  
2. Does your pharmacy have routines or procedures in place if there is a need to 
contact the prescriber? (Probe: do you get in touch with the doctor or do you 
recommend that the customer do this?) Is this the same or different if the patient 
involved is a mental health patient? 
3. How do you see your role in relation to the patient? (Probe: patient advocate, 
possibly liaising with the prescriber on behalf of the patient?) 




• Are there things you think that CPs should do for mental health patients, more than 
they do now? (Probe: more drug information, deliver to their homes, doctors’ 
intervention?)  
• Would you like to increase your role with those with mental health problems in this 
community? 
• Have you ever come across stereotyping or stigma towards mental health? Can you 
give an example? (Probe: themselves, other staff members or other health 
professionals?) 
• Do you think you might treat people differently for a mental health prescription than 
you would treat someone say for an antibiotic prescription? 




• Is there anything you would like to say about your experiences that will help me to 
understand what you’ve been telling me? 
• “If you would like to increase (or develop) your role in primary mental health care 
what would help you to do this?” – this may be answered as you work your way 
through the interview, but it may not and it is worth bearing in mind that facilitators 
and barriers often are a balance (e.g. a private consulting room is a facilitator to 
greater involvement whereas lack of a private consulting room is a barrier). 
 
All measures will be taken to protect participants’ anonymity and confidentiality. Data will only be 
handled by the research team or a contracted transcriber working under a confidentiality agreement. 
All interviewees and their data will be given a numerical code; a spreadsheet that links participants 
to their code will be stored on a password protected computer.  
 
Written consent will be obtained from all participants (see Appendix F). Participation in this research 
is entirely voluntary and participants can withdraw at any time if they choose to do so. 
  
As it is possible that the interview may raise personal issues or prompt revelations from some 
participants, it will be explicitly stated at the end of the interview that: 
 
“Some participants have said to us that this has raised personal/professional issues for them. We 
would like to advise you to seek assistance through your EAP (or equivalent) programme if this has 
been the case for you.” 
 
If anything is revealed during the course of the interviews that affects or distresses the research 













(Email Subject Line) The Community Pharmacists’ Role in Primary Mental Health Care 
2 July 2016 
Dear Participant {first name} {last name} 
Are mental health issues common in your pharmacy? Are you interested in giving us your 
views on community pharmacy and its role in primary mental health care? 
My name is Mary Wong, University of Otago research student and a pharmacist. I am 
undertaking my Master Primary Health Care under the supervision of Dr Caroline Morris and 
Eileen McKinlay in the Department Primary Health Care and General Practice, Wellington. 
Are you a practising community pharmacist? If so, you are invited to participate in my 
research project, entitled “Exploring community pharmacists’ perceptions of their role in 
primary mental health care”. Face-to-face interviews will be conducted to find out the 
mental health services that community pharmacists offer and their thoughts and views on 
this. This will increase our knowledge and understanding of what is currently being provided 
through community pharmacy and identify barriers and facilitators to the provision of 
mental health services in primary health care. 
Pharmacists recruited to this study will be asked to take part in an audio-recorded interview 
lasting between 45 and 60 minutes, at a time and location convenient to them. All 
responses to the questions will be kept confidential. In appreciation of your time a book 
voucher to the value of $25 will be given to all interviewees. Please see the attached 
information sheet for further details. If you think you may be willing to participate or want 
to discuss further then please email me at wonma250@student.otago.ac.nz 
If you have any questions then please contact me or my supervisor: 
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Mary Wong                                                                       Dr Caroline Morris 
Email: wonma250@student.otago.ac.nz             Email:caroline.morris@otago.ac.nz 
Phone 027 772 4497          Phone 04 918 6653                                                 
 












Appendix E Participant Information Sheet 
 
Exploring community pharmacists’ perceptions of their role in primary mental 
health care 
 
INFORMATION SHEET FOR PARTICIPANTS 
 
Thank you for showing an interest in this project.  Please read this information sheet carefully before 
deciding whether or not to participate.  If you decide to participate, we thank you.  If you decide not 
to take part there will be no disadvantage to you and we thank you for considering our request.   
 
What is the aim of the project? 
This project aims to explore your views regarding community pharmacists’ provision of pharmacy 
services to those with mental health issues. This primarily involves depression, anxiety and mixed 
anxiety and depressive issues. The project also aims to identify barriers and facilitators to providing 
these services. 
 
Who will be interviewed? 
Community pharmacists who are willing to discuss their experiences and perceptions of providing 
mental health services will be interviewed. 
 
What will I be asked to do? 
You will be asked to participate in a face-to-face interview that will take between 45 minutes and an 
hour of your time. The interview will be carried out by Mary Wong, the research student, and will 
involve a range of questions. The general line of questioning is based on your perceptions of your 
role in mental health care and the mental health services that you provide. The precise questions 
will depend on the way in which the interview develops. A book voucher to the value of $25 will be 
given at the end of the interview. 
 
What data or information will be collected about me and how will it be used?  
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There will be some personal information collected, which will only be used for demographic 
purposes. The interview will be audio-taped and the information transcribed. The electronic files will 
be kept in a password protected computer and hard copy files of data will be stored in a locked filing 
cabinet in secure premises. Only the research team consisting of the researcher, the supervisors and 
a transcriber will have access to this information. Any raw data on which the results of this project 
depend, including the digital audio files and transcribed interviews, will be retained in secure 
storage for ten years after which time they will be destroyed. 
You will be given the opportunity to review the content of the transcribed interview and make any 
amendments.  The results of the project may be published and will be available in the University of 
Otago (Dunedin, New Zealand) but every attempt will be made to preserve your anonymity. All 
material will be anonymised, including any direct quotes that are included. 
 
On the Consent Form there are options regarding your anonymity. Please be aware that should you 
wish we will make every attempt to preserve your anonymity. However, with your consent there are 
some cases where it would be preferable to attribute contributions made to individual participants, 
although participants are not identified. It is absolutely up to you which of these options you prefer. 
 
You will be offered a short summary of findings at the conclusion of the project. 
 
The project has been reviewed and approved under Category B Application for Ethical review by the 
Department Primary Health Care and General Practice, University of Otago Wellington. 
 
Can I change my mind and withdraw from the project? 
Yes, you can change your mind and may withdraw from the project at any time and without any 
disadvantage to yourself.  
 
What if I have any questions? 
If you have any questions about this research project either now or in the future, please feel free to 
contact either: 
Mary Wong                                                                Dr Caroline Morris 
Email:wonma250@student.otago.ac.nz                                Dept. of Primary Health Care and General Practice                                           
  
Ph 027 772 4497  Email: caroline.morris@otago.ac.nz 
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  Ph. 04 918 6653 
 
 
 This study has been approved by the Department stated above. However, if you have any concerns 
about the ethical conduct of the research you may contact the University of Otago Human Ethics 
Committee through the Human Ethics Committee Administrator (phone 03 479-8256). Any issues 









Exploring community pharmacists’ perceptions of their role in                       
primary mental health care. 
 
                                             CONSENT FORM FOR COMMUNITY PHARMACISTS 
 
I have read the Information Sheet concerning this project and understand what it is about.  
All my questions have been answered to my satisfaction.  I understand that I am free to 
request further information at any stage. 
I know that: - 
1. My participation in the project is entirely voluntary 
 
2. I am free to withdraw from the project at any time without any disadvantage 
 
3. I will be participating in an interview regarding my thoughts on community 
pharmacists’ role in primary mental health care. This project involves an open-
questioning interview technique. The precise nature of all the questions which will be 
asked have not been determined in advance, but will depend on the way in which the 
interview develops. In the event that the line of questioning develops in such a way 
that I feel hesitant or uncomfortable I may decline to answer any particular 
question(s) 
 
4. Personal identifying information will be destroyed at the conclusion of the project but 
any raw data on which the results of the project depend will be retained in secure 
storage for at least five years. All audio-tapes, emails, electronic audio files and 
transcripts will only be kept until the end of the research at which stage they will all 
be deleted. 
 
5. There is no discomfort or known physical or psychological risk if I participate in this 
interview process 
 
6. A book token to the value of $25 will be given in appreciation of my contribution to 




7. The results of the project may be published and will be available in the University of 
Otago Library (Dunedin, New Zealand) but every attempt will be made to preserve 
my anonymity.   
 
 I agree to take part in this project. 
 
........................................................   ............................... 







Appendix G Demographics Form 
DEMOGRAPHIC DATA FORM 
 
WE WOULD LIKE SOME MORE INFORMATION ABOUT YOU.  
 
Thank you for taking the time to fill this in. 
 
1. Are you Woman / Man / Gender Diverse / Prefer not to say?  Please underline one. 
2. Which age range are you in? 
Age Range in years Add tick 







   
3. Which ethnic group/s do you belong to? (please tick the appropriate space or spaces) 
 
Ethnic Group Add ticks where 
applicable 
New Zealand European  
Māori  
Samoan  





































Anxiety: Anxiety disorders defined by the World Health Organization (WHO) refers to a 
group of mental disorders that have characteristic feelings of anxiety and fear, with 
symptoms ranging from mild to severe.4 Anxiety can be classified into four groups to include 
generalised anxiety disorders (GAD), phobias, obsessive compulsive disorder, and 
posttraumatic stress disorder (PTSD).113 
Counsell/Pharmacist counselling: Counselling by pharmacists has a different interpretation 
from that of counselling by other health professionals such as psychiatrists or psychologists. 
CPs use this term to describe the interaction with their patients when they advise or give 
any information regarding any aspect of their medication and related medical conditions. It 
can include such things as appropriate drug dosages, side effects of their medication, 
medication management, and any health and well-being issues. 
Depression: In 2017, the WHO explained depression or depressive disorders as being 
characterised by sadness, loss of interest or pleasure, feelings of guilt or low self-worth, 
disturbed sleep or appetite, feelings of tiredness and poor concentration.4 Depression may 
be classified as mild, moderate or severe. Depressive disorders may be classified further into 
depressive disorders or dysthymia. The diagnosis of dysthymia is a persistent or chronic 
form of mild depression but has a tendency to be less intense and longer lasting.  
District Health Boards: Are governed by a board made up of up to eleven members, of 
which four are appointed by the Minister of Health. They are responsible for the provision, 
or funding the provision, of health and disability services in their designated areas. There 
are currently twenty DHBs in New Zealand. 
Pacifica/Pacific peoples: These are people living in New Zealand who have emigrated from 
or identify culturally with people in the Pacific region including Cook Islands, Fiji, Niue, 
Samoa, Tokelau and Tonga. 
Primary Health Care: Professional health care provided in the community setting. This 
includes GPs, nurse practitioners, nurse prescribers, pharmacists, dentists and midwives and 
is the first point of contact in the health care process. 
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Primary Health Organisation: Organisations that are funded to support the provision of 
essential primary health care services, through general practices. 
Randomised controlled trials: These are controlled experiments with two or more 
interventions in participants who are assigned randomly to either intervention or control 
(which may be no intervention). The outcomes are measurable and are therefore known as 
quantitative studies. 
Secondary Health Care: Specialist care that is generally provided in a hospital setting. 
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